

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

10/016850

=>
Uploading 8504.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 00:43:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 582 TO ITERATE

100.0% PROCESSED 582 ITERATIONS 50 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10193 TO 13087
PROJECTED ANSWERS: 576 TO 1424

L2 50 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 00:43:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11751 TO ITERATE

100.0% PROCESSED 11751 ITERATIONS 1078 ANSWERS
SEARCH TIME: 00.00.01

L3 1078 SEA SSS FUL L1

=> file hcaplus, uspatfull

Delacroix

10/016850

FILE 'HCAPLUS' ENTERED AT 00:44:08 ON 30 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 00:44:08 ON 30 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 13 and adrenerg?
L4 12 L3 AND ADRENERG?

=> s 14 and (link? or covalent? or conjugat?)
L5 8 L4 AND (LINK? OR COVALENT? OR CONJUGAT?)

=> dup rem 15
PROCESSING COMPLETED FOR L5
L6 8 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 abs ibib kwic hitstr 1-8

L6 ANSWER 1 OF 8 USPATFULL on STN

AB The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:243617 USPATFULL

TITLE: Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation

INVENTOR(S): Sircar, Jagadish C., San Diego, CA, UNITED STATES
Richards, Mark L., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132808	A1	20020919
APPLICATION INFO.:	US 2002-90044	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275260P	20010312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660	

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 1736

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-link immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators, . . .

SUMM [0009] A number of drugs are available for the palliative treatment of

Delacroix

asthma; however, their efficacies vary markedly. Short-acting .beta..sub.2-adrenergic agonists, terbutaline and albuterol, long the mainstay of asthma treatment, act primarily during the early phase as bronchodilators. The newer. . .

SUMM [0056] The at least one additional active ingredient may be a short-acting .beta..sub.2-adrenergic agonist selected from the group consisting of terbutaline and albuterol; a long-acting .beta..sub.2-adrenergic agonist selected from the group consisting of salmeterol and formoterol; an antihistamine selected from the group consisting of loratadine, azelastine. . .

DETD . . . some of the tested cell lines and previous Western blot results with the compounds, there is evidence to suggest a link between NF-.kappa.B inhibition and the action of the drugs. Breast cancer cells offer a good model for testing this phenomenon. . .

CLM What is claimed is:
 . . . method of claim 6, wherein said at least one additional ingredient is selected from the group consisting of a short-acting .beta..sub.2-adrenergic agonist, a long-acting .beta..sub.2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor. . .
 14. The method of claim 13, wherein said additional ingredient is selected from the group consisting of a short-acting .beta..sub.2-adrenergic agonist, a long-acting .beta..sub.2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor. . .


IT	459807-38-6P	459807-39-7P	459807-40-0P	459807-41-1P
	459807-42-2P	459807-43-3P	459807-44-4P	459807-45-5P
	459807-46-6P	459807-47-7P	459807-48-8P	459807-49-9P
	459807-51-3P	459807-52-4P	459807-53-5P	459807-54-6P
	459807-56-8P	459807-57-9P	459807-58-0P	459807-59-1P
	459807-61-5P	459807-62-6P	459807-63-7P	459807-64-8P
	459807-66-0P	459807-67-1P	459807-68-2P	459807-69-3P
	459807-71-7P	459807-72-8P	459807-73-9P	459807-74-0P
	459807-76-2P	459807-77-3P	459807-78-4P	459807-79-5P
	459807-81-9P	459807-82-0P	459807-83-1P	459807-84-2P
	459807-86-4P	459807-87-5P	459807-88-6P	459807-89-7P
	459807-91-1P	459807-92-2P	459807-93-3P	459807-94-4P
	459807-96-6P	459807-97-7P	459807-98-8P	459807-99-9P
	459808-01-6P	459808-02-7P	459808-03-8P	459808-04-9P
	459808-06-1P	459808-07-2P	459808-08-3P	459808-09-4P
	459808-11-8P	459808-12-9P	459808-13-0P	459808-14-1P
	459808-16-3P	459808-17-4P	459808-18-5P	459808-19-6P
	459808-21-0P	459808-22-1P	459808-23-2P	459808-24-3P
	459808-26-5P	459808-27-6P	459808-28-7P	459808-29-8P
	459808-31-2P	459808-32-3P	459808-33-4P	459808-34-5P
	459808-36-7P	459808-37-8P	459808-38-9P	459808-39-0P
	459808-41-4P	459808-42-5P	459808-43-6P	459808-44-7P
	459808-46-9P	459808-47-0P	459808-48-1P	459808-49-2P
	459808-51-6P	459808-52-7P	459808-53-8P	459808-54-9P
	459808-56-1P	459808-57-2P	459808-58-3P	459808-59-4P
	459808-61-8P	459808-62-9P	459808-63-0P	459808-64-1P
	459808-66-3P	459808-67-4P	459808-68-5P	459808-69-6P
	459808-71-0P	459808-72-1P	459808-73-2P	459808-74-3P
	459808-76-5P	459808-77-6P	459808-78-7P	459808-79-8P
	459808-81-2P	459808-82-3P	459808-83-4P	459808-84-5P
	459808-86-7P	459808-87-8P	459808-88-9P	459808-89-0P

459808-91-4P 459808-92-5P 459808-93-6P 459808-94-7P 459808-95-8P
 459808-96-9P 459808-97-0P 459808-98-1P 459808-99-2P 459809-00-8P
 459809-01-9P 459809-02-0P 459809-03-1P 459809-04-2P 459809-05-3P
 459809-06-4P 459809-07-5P 459809-08-6P 459809-09-7P 459809-10-0P
 459809-11-1P 459809-12-2P 459809-13-3P 459809-14-4P 459809-15-5P
 459809-16-6P 459809-17-7P 459809-18-8P 459809-19-9P 459809-20-2P
 (prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and
 analogs as IgE and cell proliferation inhibitors)

IT 459807-42-2P
 (prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and
 analogs as IgE and cell proliferation inhibitors)

RN 459807-42-2 USPATFULL

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-[(methyltricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]phenyl]-1H-benzimidazol-5-yl] - (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 sub A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4747 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Audia, James E., Indianapolis, IN, United States

Hibschman, David J., Bargersville, IN, United States

Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Nissen, Jeffrey S., Fishers, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

Wong, David T., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6172073 B1 20010109

APPLICATION INFO.: US 1998-49837 19980327 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789
 Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DOCUMENT TYPE: Patent

FILE SEGMENT: Granted
 PRIMARY EXAMINER: Raymond, Richard L.
 LEGAL REPRESENTATIVE: Lentz, Nelsen L.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-adrenergic activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 ethylene groups may be in the linker alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be linked in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-linked group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-linked fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-adrenergic or .beta.-adrenergic activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT	55581-45-8P	73889-11-9P	180156-51-8P	180156-53-0P	180156-54-1P
	180156-56-3P	180156-58-5P	180156-60-9P	180156-61-0P	180156-63-2P
	180156-65-4P	180156-67-6P	180156-69-8P	180156-71-2P	180156-73-4P
	180156-75-6P	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P
	180156-85-8P	180156-87-0P	180156-89-2P	180156-91-6P	180156-92-7P
	180156-94-9P	180156-96-1P	180156-98-3P	180157-00-0P	180157-02-2P
	180157-04-4P	180157-06-6P	180157-08-8P	180157-10-2P	180157-12-4P
	180157-14-6P	180157-16-8P	180157-18-0P	180157-20-4P	180157-22-6P
	180157-24-8P	180157-26-0P	180157-28-2P	180157-30-6P	180157-32-8P
	180157-34-0P	180157-36-2P	180157-38-4P	180157-40-8P	180157-42-0P
	180157-44-2P	180157-46-4P	180157-48-6P	180157-50-0P	180157-52-2P
	180157-54-4P	180157-56-6P	180157-58-8P	180157-60-2P	180157-62-4P
	180157-64-6P	180157-66-8P	180157-68-0P	180157-70-4P	180157-72-6P
	180157-74-8P	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P
	180157-84-0P	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P
	180157-94-2P	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
	180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
	180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
	180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
	180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
	180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
	180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
	180158-53-6P	180158-54-7P	180158-55-8P	180158-57-0P	180158-58-1P
	180158-59-2P	180158-60-5P	180158-61-6P	180158-63-8P	180158-65-0P
	180158-67-2P	180158-69-4P	180158-71-8P	180158-73-0P	180158-75-2P

10/016850

180158-77-4P 180158-79-6P 180158-81-0P 180158-83-2P 180158-85-4P
180158-87-6P 180158-89-8P 180158-90-1P 180158-91-2P 180158-92-3P
180158-93-4P 180158-94-5P 180158-95-6P 180158-96-7P 180158-97-8P
180158-98-9P 180158-99-0P 180159-00-6P 180159-01-7P 180159-03-9P
180159-05-1P 180159-07-3P 180159-09-5P 180159-11-9P 180159-12-0P
180159-13-1P 180159-14-2P 180159-15-3P 180159-16-4P 180159-17-5P
180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P 180159-22-2P
180159-23-3P 180159-24-4P 180159-25-5P 180159-26-6P 180159-27-7P
180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P 180159-35-7P
180159-37-9P 180159-39-1P 180159-41-5P 180159-43-7P 180159-45-9P
180159-47-1P 180159-49-3P 180159-51-7P 180159-53-9P 180159-55-1P
180159-57-3P 180159-59-5P 180159-61-9P 180159-63-1P 180159-65-3P
180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P
180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P
180159-87-9P 180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P
180159-95-9P 180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P
180160-00-3P 180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P
180160-05-8P 180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P
180160-10-5P 180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P
180160-15-0P 180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P
180160-20-7P 180160-21-8P 180160-22-9P 180160-23-0P 180160-24-1P
180160-25-2P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

IT 180160-26-3P 180160-27-4P 180160-28-5P 180160-29-6P 180160-30-9P
180160-31-0P 180160-32-1P 180160-33-2P 180160-34-3P
180160-35-4P 180160-36-5P 180271-36-7P


(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

IT 180158-52-5P 180160-33-2P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




® HCl

RN 180160-33-2 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Delacroix



L6 ANSWER 3 OF 8 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoyl amide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkyl acylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:41028 USPATFULL
 TITLE: Method of synergistic treatment for benign prostatic hyperplasia
 INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
 Stoner, Elizabeth, Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046183		20000404
APPLICATION INFO.:	US 1998-27105		19980220 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-428595, filed on 25 Apr 1995, now patented, Pat. No. US 5753641 which is a continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 20 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5342		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as. . .

SUMM . . . prostatic hyperplasia (BPH), involving combination therapy of administering therapeutically effective amounts of a 5.alpha.-reductase inhibitor in combination with an .alpha..sub.1 -adrenergic receptor blocker.

SUMM . . . thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly an .alpha..sub.1 -adrenergic receptor blocking agent, also termed herein ".alpha..sub.1 -blocker".

SUMM Thus, the combined effect of a 5.alpha.-reductase inhibitor in inhibiting DHT production in the prostate and the .alpha..sub.1 -adrenergic receptor blocker, i.e. terazosin, will result in a greater effect on suppressing the growth and symptomatic relief of enlarged prostate. . .

SUMM Alpha..sub.1 -adrenergic receptor blockers function generally as anti-hypertensive agents by blocking .alpha.-adrenergic receptor sites. They relax stromal (smooth) tissue in the bladder, which cause fibrous tissue to contract when stimulated by noradrenaline. . .

SUMM .alpha.-Adrenergic blocking agents bind selectively to the .alpha. class of adrenergic receptors and thereby interfere with the capacity of sympathomimetic amines to initiate actions at these sites.

SUMM There are prominent differences in the relative abilities of .alpha.-adrenergic blocking agents to antagonize the effects of sympathomimetic amines at the two subtypes of a receptors. It is known that. . . selective .alpha..sub.1 -blocking agent, while phentolamine is only three to five times more potent in inhibiting .alpha..sub.1 -than .alpha..sub.2 -adrenergic receptors. In contrast, yohimbine is a selective .alpha..sub.2 -blocker and has been shown to prevent the antihypertensive effects of clonidine, . . .

SUMM However, preferred in this invention are .alpha.-adrenergic blockers which preferably be .alpha..sub.1 -blockers and have little or no .alpha..sub.2 -blocking activity.

SUMM Examples of .alpha.-adrenergic receptor blockers are terazosin (Abbott-Hytrin*) whose chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine, as described in German Patent 2,646, 186 and U.S. Pat. . .

SUMM . . . invention, prepared in accordance with the method described above, are, as already described, potent agents in combination with an alpha-one adrenergic receptor blocker for the treatment of BPH.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are linked together are cyclopentane, cyclohexane or a benzene ring; and

SUMM . . . with the methods described above, are, as already described, can be used to treat BPH in combination with an alpha adrenergic blocker by oral, parenteral or topical administration.

SUMM In this invention, the a..sub.1 -adrenergic receptor blocker, and the 5a-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral. . .

IT 98319-25-6P 98319-28-9P 98319-29-0P 103335-45-1P 103335-46-2P

103335-48-4P	103335-56-4P	103335-57-5P	103497-68-3P	119169-78-7P
119347-91-0P	119347-96-5P	119348-05-9P	133216-44-1P	134067-56-4P
134067-64-4P	134217-16-6P	134217-17-7P	138715-91-0P	139229-87-1P
139229-88-2P	139229-89-3P	139229-90-6P	139229-91-7P	139229-92-8P
139229-93-9P	139229-94-0P	139229-95-1P	139229-97-3P	139230-03-8P
139230-04-9P	139255-63-3P	139344-08-4P	139344-09-5P	139512-72-4P
139512-73-5P	139512-75-7P	139512-76-8P	139512-77-9P	139512-78-0P
139512-79-1P	139512-80-4P	139523-47-0P	139539-84-7P	139755-31-0P
144879-06-1P	144879-08-3P	144879-10-7P	144879-16-3P	144879-17-4P
144879-18-5P	144879-21-0P	144879-25-4P	144879-27-6P	144879-29-8P
144879-32-3P	144879-33-4P	144879-34-5P	144879-35-6P	144879-36-7P
144879-37-8P	144879-38-9P	144879-39-0P	144879-40-3P	144879-41-4P
144879-48-1P	144879-50-5P	144879-55-0P	144879-60-7P	145191-61-3P
146032-67-9P	146032-69-1P	146057-96-7P	146142-97-4P	
146143-98-8P				

(prepn. of)


IT **146032-67-9P**

(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 8 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacetylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:54885 USPATFULL
 TITLE: Method of treatment for benign prostatic hyperplasia
 INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
 Stoner, Elizabeth, Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5753641		19980519
APPLICATION INFO.:	US 1995-428595		19950425 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 10 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., Nicholson, William H.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5371		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	. . . alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α .sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as. . .		
SUMM	. . . prostatic hyperplasia (BPH), involving combination therapy of administering therapeutically effective amounts of a 5. α .-reductase inhibitor in combination with an α .sub.1 -adrenergic receptor blocker.		
SUMM	. . . thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly an α .sub.1 -adrenergic receptor blocking agent, also termed herein ". α .sub.1 -blocker".		
SUMM	Thus, the combined effect of a 5. α .-reductase inhibitor in inhibiting DHT production in the prostate and the α .sub.1 -adrenergic receptor blocker, i.e. terazosin, will result in a greater effect on suppressing the growth and symptomatic relief of enlarged prostate. . .		
SUMM	Alpha.sub.1 -adrenergic receptor blockers function generally as anti-hypertensive agents by blocking α .-adrenergic receptor sites. They relax stromal (smooth) tissue in the bladder, which cause fibrous tissue to contract when stimulated by noradrenaline. . .		
SUMM	α .-Adrenergic blocking agents bind selectively to the α . class of adrenergic receptors and thereby interfere with the capacity of sympathomimetic amines to initiate actions at these sites.		
SUMM	There are prominent differences in the relative abilities of α .-adrenergic blocking agents to antagonize the effects of sympathomimetic amines at the two subtypes of α . receptors. It is known that. . . selective α .sub.1 -blocking agent, while		

phentolamine is only three to five times more potent in inhibiting .alpha..sub.1 - than .alpha..sub.2 -adrenergic receptors. In contrast, yohimbine is a selective .alpha..sub.2 -blocker and has been shown to prevent the antihypertensive effects of clonidine, . . .

SUMM However, preferred in this invention are .alpha.-adrenergic blockers which preferably be .alpha..sub.1 -blockers and have little or no .alpha..sub.2 -blocking activity.

SUMM Examples of .alpha.-adrenergic receptor blockers are terazosin (Abbott-Hytrin*) whose chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine, as described in German Patent 2,646,186 and U.S. Pat. No. . . .

SUMM . . . invention, prepared in accordance with the method described above, are, as already described, potent agents in combination with an alpha-one adrenergic receptor blocker for the treatment of BPH.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are linked together are cyclopentane, cyclohexane or a benzene ring; and

SUMM . . . with the methods described above, are, as already described, can be used to treat BPH in combination with an alpha adrenergic blocker by oral, parenteral or topical administration.

SUMM In this invention, the .alpha..sub.1 -adrenergic receptor blocker, and the 5a-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral. . .


IT	98319-25-6P	98319-28-9P	98319-29-0P	103335-45-1P	103335-46-2P
	103335-48-4P	103335-56-4P	103335-57-5P	103497-68-3P	119169-78-7P
	119347-91-0P	119347-96-5P	119348-05-9P	133216-44-1P	134067-56-4P
	134067-64-4P	134217-16-6P	134217-17-7P	138715-91-0P	139229-87-1P
	139229-88-2P	139229-89-3P	139229-90-6P	139229-91-7P	139229-92-8P
	139229-93-9P	139229-94-0P	139229-95-1P	139229-97-3P	139230-03-8P
	139230-04-9P	139255-63-3P	139344-08-4P	139344-09-5P	139512-72-4P
	139512-73-5P	139512-75-7P	139512-76-8P	139512-77-9P	139512-78-0P
	139512-79-1P	139512-80-4P	139523-47-0P	139539-84-7P	139755-31-0P
	144879-06-1P	144879-08-3P	144879-10-7P	144879-16-3P	144879-17-4P
	144879-18-5P	144879-21-0P	144879-25-4P	144879-27-6P	144879-29-8P
	144879-32-3P	144879-33-4P	144879-34-5P	144879-35-6P	144879-36-7P
	144879-37-8P	144879-38-9P	144879-39-0P	144879-40-3P	144879-41-4P
	144879-48-1P	144879-50-5P	144879-55-0P	144879-60-7P	145191-61-3P
	146032-67-9P	146032-69-1P	146057-96-7P	146142-97-4P	
	146143-98-8P				
	(prepn. of)				

IT 146032-67-9P
(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1._{sub}A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:42357 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Hibscher, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5741789 19980421

APPLICATION INFO.: US 1995-467434 19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed
on 17 Jan 1995, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Shah, Mukund J.

ASSISTANT EXAMINER: Kifle, Bruck

LEGAL REPRESENTATIVE: Palmberg, Arleen, Boone, David E.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 5902

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-adrenergic activity. More recently, it has become possible to study the function of drugs at individual receptors *in vitro* or ex. . . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . . .

SUMM It may be noted again that bulky R.^{sup.3} groups such as dibenzocycloheptene or naphthyl may be linked in any reasonable orientation, as may substituent parts of the R.^{sup.3} group such as piperazinonyl.

SUMM The spiro-linked group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-linked fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1._{sub}.A receptor antagonists typically have .alpha.-adrenergic or .beta.-adrenergic activity as well, and are therefore nonselective for 5HT-1._{sub}.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . . .

IT	180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
	180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
	180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
	180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
	180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
	180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
	180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
	180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
	180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
	180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
	180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
	180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
	180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
	180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
	180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
	180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
	180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
	180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
	180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
	180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
	180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
	180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
	180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
	180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
	180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
	180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P
	180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
	180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
	180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
	180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
	180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
	180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P

10/016850


180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P 180160-00-3P
180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P 180160-05-8P
180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P 180160-10-5P
180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P 180160-15-0P
180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P 180160-20-7P
180160-21-8P 180271-36-7P 185255-45-2P 185255-47-4P 185255-49-6P
185255-51-0P 185255-53-2P 185255-55-4P 185255-67-8P 185255-71-4P
185255-73-6P 190785-69-4P 190786-32-4P 190786-36-8P 190788-23-9P
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and
reuptake inhibitors)

IT 180158-52-5P
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and
reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L6 ANSWER 6 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:38539 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Audia, James E., Indianapolis, IN, United States

Hibschman, David J., Bargersville, IN, United States

Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Nissen, Jeffrey S., Fishers, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

Wong, David T., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States

Delacroix

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627196		19970506
APPLICATION INFO.:	US 1995-468948		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Bottino, Anthony		
LEGAL REPRESENTATIVE:	Jones, Joseph A., Boone, David E.		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5947		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-adrenergic activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the linker alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be linked in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-linked group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-linked fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-adrenergic or .beta.-adrenergic activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT	180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
	180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
	180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
	180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
	180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
	180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
	180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
	180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
	180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
	180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
	180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P

180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P
180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P
180159-96-0P	180159-97-1P	180159-98-2P	180159-99-3P	180160-00-3P
180160-01-4P	180160-02-5P	180160-03-6P	180160-04-7P	180160-05-8P
180160-06-9P	180160-07-0P	180160-08-1P	180160-09-2P	180160-10-5P
180160-11-6P	180160-12-7P	180160-13-8P	180160-14-9P	180160-15-0P
180160-16-1P	180160-17-2P	180160-18-3P	180160-19-4P	180160-20-7P
180160-21-8P	180271-36-7P	185255-45-2P	185255-47-4P	185255-49-6P
185255-51-0P	185255-53-2P	185255-55-4P	185255-67-8P	185255-71-4P
185255-73-6P	190785-69-4P	190786-32-4P	190786-36-8P	190788-23-9P

(prepn. of heterocyclxyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)


IT 180158-52-5P

(prepn. of heterocyclxyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



○ HCl

L6 ANSWER 7 OF 8 USPATFULL on STN

Delacroix

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1._{sub}A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:106493 USPATFULL
 TITLE: Compounds having effects on serotonin-related systems
 INVENTOR(S): Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576321		19961119
APPLICATION INFO.:	US 1995-468900		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Bottino, Anthony		
LEGAL REPRESENTATIVE:	Jones, Joseph A., Boone, David E.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5725		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-adrenergic activity. More recently, it has become possible to study the function of drugs at individual receptors *in vitro* or ex. . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.³ groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.³ group such as piperazinonyl.

SUMM The **spiro-linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a **spiro-linked** fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1._{sub}A receptor antagonists typically have .alpha.-adrenergic or .beta.-adrenergic activity as well, and are therefore nonselective for 5HT-1._{sub}A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering,

10/016850

cleansing and the like, beyond any. . .

IT 55581-45-8P 73889-11-9P 180156-51-8P 180156-54-1P 180156-56-3P
180156-60-9P 180156-61-0P 180156-63-2P 180156-67-6P 180156-69-8P
180156-73-4P 180156-75-6P 180156-77-8P 180156-79-0P 180156-81-4P
180156-83-6P 180156-85-8P 180156-87-0P 180156-89-2P 180156-91-6P
180156-92-7P 180156-94-9P 180156-96-1P 180156-98-3P 180157-00-0P
180157-02-2P 180157-04-4P 180157-06-6P 180157-08-8P 180157-10-2P
180157-12-4P 180157-14-6P 180157-16-8P 180157-18-0P 180157-20-4P
180157-22-6P 180157-24-8P 180157-26-0P 180157-28-2P 180157-30-6P
180157-34-0P 180157-36-2P 180157-38-4P 180157-40-8P 180157-42-0P
180157-44-2P 180157-46-4P 180157-50-0P 180157-52-2P 180157-54-4P
180157-56-6P 180157-58-8P 180157-60-2P 180157-62-4P 180157-64-6P
180157-66-8P 180157-68-0P 180157-70-4P 180157-72-6P 180157-74-8P
180157-76-0P 180157-78-2P 180157-80-6P 180157-82-8P 180157-84-0P
180157-86-2P 180157-88-4P 180157-90-8P 180157-92-0P 180157-94-2P
180157-95-3P 180157-96-4P 180157-98-6P 180158-00-3P 180158-02-5P
180158-04-7P 180158-06-9P 180158-08-1P 180158-10-5P 180158-12-7P
180158-15-0P 180158-17-2P 180158-19-4P 180158-22-9P 180158-24-1P
180158-26-3P 180158-28-5P 180158-30-9P 180158-32-1P 180158-34-3P
180158-36-5P 180158-38-7P 180158-39-8P 180158-40-1P 180158-41-2P
180158-42-3P 180158-43-4P 180158-44-5P 180158-45-6P 180158-46-7P
180158-47-8P 180158-48-9P 180158-49-0P 180158-50-3P 180158-51-4P
180158-52-5P 180158-53-6P 180158-54-7P 180158-55-8P
180158-57-0P 180158-58-1P 180158-59-2P 180158-60-5P 180158-61-6P
180158-65-0P 180158-67-2P 180158-69-4P 180158-71-8P 180158-73-0P
180158-75-2P 180158-77-4P 180158-79-6P 180158-81-0P 180158-83-2P
180158-85-4P 180158-87-6P 180158-89-8P 180158-90-1P 180158-91-2P
180158-92-3P 180158-93-4P 180158-94-5P 180158-97-8P 180158-98-9P
180159-01-7P 180159-03-9P 180159-07-3P 180159-09-5P 180159-11-9P
180159-12-0P 180159-13-1P 180159-14-2P 180159-15-3P 180159-16-4P
180159-17-5P 180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P
180159-22-2P 180159-23-3P 180159-24-4P 180159-25-5P 180159-26-6P
180159-27-7P 180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P
180159-34-6P 180159-35-7P 180159-37-9P 180159-39-1P 180159-41-5P
180159-43-7P 180159-45-9P 180159-47-1P 180159-49-3P 180159-51-7P
180159-53-9P 180159-55-1P 180159-57-3P 180159-59-5P 180159-63-1P
180159-65-3P 180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P
180159-75-5P 180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P
180159-84-6P 180159-85-7P 180159-87-9P 180159-89-1P 180159-91-5P
180159-93-7P 180159-94-8P 180159-95-9P 180159-96-0P 180159-97-1P
180159-98-2P 180159-99-3P 180160-00-3P 180160-01-4P 180160-02-5P
180160-03-6P 180160-04-7P 180160-05-8P 180160-06-9P 180160-07-0P
180160-08-1P 180160-09-2P 180160-10-5P 180160-11-6P 180160-12-7P
180160-13-8P 180160-14-9P 180160-15-0P 180160-16-1P 180160-17-2P
180160-18-3P 180160-19-4P 180160-20-7P 180160-22-9P 180160-23-0P
180160-24-1P 180160-25-2P 180160-26-3P 180160-27-4P 180160-28-5P
180160-29-6P 180160-30-9P 180160-31-0P 180160-32-1P
180160-33-2P 180160-34-3P 180160-35-4P 180160-36-5P
180271-36-7P 185255-45-2P

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and
analogs as 5-HT1A receptor ligands)

IT **180158-52-5P 180160-33-2P**

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and
analogs as 5-HT1A receptor ligands)


RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Delacroix

10/016850

Absolute stereochemistry.




● HCl

RN 180160-33-2 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 8 USPATFULL on STN

AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.A is ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:91061 USPATFULL

TITLE: Carbostyril oxytocin receptor antagonists

INVENTOR(S):
Freidinger, Roger M., Lansdale, PA, United States
Pawluczyk, Joseph M., Warminster, PA, United States
Pettibone, Douglas J., Shalfont, PA, United States
Williams, Peter D., Harleysville, PA, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5356904		19941018
APPLICATION INFO.:	US 1992-957491		19921007 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cintins, Marianne M.		

Delacroix

ASSISTANT EXAMINER: Travers, Russell
 LEGAL REPRESENTATIVE: Appollina, Mary A., DiPrima, Joseph F.
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Tocolytic (uterine-relaxing) agents that are currently in use include .beta..sub.2 -adrenergic agonists, magnesium sulfate and calcium antagonists. Ritodrine, the leading .beta..sub.2 -adrenergic agonists, causes a number of cardiovascular and metabolic side effects in the mother, including tachycardia, increased renin secretion, hyperglycemia (and reactive hypoglycemia in the infant) and pulmonary edema. Other .beta..sub.2 -adrenergic agonists, including terbutaline and albuterol have side effects similar to those of ritodrine. Magnesium sulfate at plasma concentrations above the. .

DETD . . . achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrlates and cross-linked or amphipathic block copolymers of hydrogels.

IT	131582-88-2P	131582-89-3P	131582-90-6P	131582-91-7P	131582-97-3P
	131582-99-5P	131583-01-2P	131583-04-5P	131583-05-6P	131583-06-7P
	131583-07-8P	131583-08-9P	131583-09-0P	131583-10-3P	
	131583-11-4P	131583-13-6P	131583-14-7P	131583-15-8P	131583-17-0P
	131583-18-1P	131583-19-2P	131583-20-5P	131583-21-6P	131583-23-8P
	131583-24-9P	131583-26-1P	131583-27-2P	131583-28-3P	131583-29-4P
	131583-30-7P	131583-31-8P	131583-33-0P	131583-34-1P	131583-35-2P
	131583-36-3P	131583-37-4P	131583-38-5P	131583-39-6P	131583-40-9P
	131583-41-0P	131583-42-1P	131583-43-2P	131583-44-3P	131583-45-4P
	131583-46-5P	131583-49-8P	131583-50-1P	131583-51-2P	131583-52-3P
	131583-53-4P	131583-57-8P	131583-58-9P	131583-60-3P	131583-61-4P
	131583-63-6P	131583-64-7P	131583-65-8P	131583-66-9P	131583-67-0P
	131583-71-6P	131583-72-7P	131583-74-9P	131583-75-0P	131583-76-1P
	131583-77-2P	131583-79-4P	131583-81-8P	131583-83-0P	131583-84-1P
	131583-87-4P	131583-88-5P	131583-89-6P	131583-90-9P	131583-91-0P
	131583-92-1P	131583-93-2P	131583-95-4P	131583-96-5P	131583-97-6P
	131583-98-7P	131583-99-8P	131584-01-5P	131584-02-6P	131584-03-7P
	131584-04-8P	131584-05-9P	131584-07-1P	131584-09-3P	131584-11-7P
	131584-12-8P	131584-13-9P	131584-14-0P	131584-15-1P	131584-16-2P
	131584-17-3P	131584-18-4P	131584-19-5P	131584-20-8P	131584-21-9P
	131584-22-0P	131584-23-1P	131584-24-2P	131584-25-3P	131584-26-4P
	131584-27-5P	131584-28-6P	131584-29-7P	131584-30-0P	131584-33-3P
	131584-36-6P	131584-37-7P	131584-38-8P	131584-40-2P	131584-41-3P
	131584-42-4P	131584-43-5P	131584-44-6P	131584-45-7P	131584-46-8P
	131584-47-9P	131584-48-0P	131584-49-1P	131584-50-4P	131584-51-5P
	131584-52-6P	131584-53-7P	131584-54-8P	131584-55-9P	131584-56-0P
	131584-57-1P	131584-58-2P	131584-59-3P	131584-60-6P	131584-61-7P
	131584-62-8P	131584-63-9P	131584-64-0P	131584-65-1P	131584-66-2P
	131584-67-3P	131584-68-4P	131584-69-5P	131584-70-8P	131584-71-9P
	131584-73-1P	131584-74-2P	131584-76-4P	131584-77-5P	131584-78-6P
	131584-79-7P	131584-80-0P	131584-81-1P	131584-82-2P	131584-83-3P
	131584-85-5P	131584-87-7P	131584-88-8P	131584-89-9P	131584-90-2P
	131584-92-4P	131584-93-5P	131584-94-6P	131584-95-7P	131584-98-0P
	131584-99-1P	131585-00-7P	131585-01-8P	131585-02-9P	131585-03-0P
	131585-04-1P	131585-05-2P	131585-06-3P	131585-07-4P	131585-08-5P
	131585-09-6P	131585-10-9P	131585-11-0P	131585-12-1P	131585-13-2P
	131585-14-3P	131585-15-4P	131585-16-5P	131585-17-6P	131585-18-7P
	131585-19-8P	131585-22-3P	131585-23-4P	131585-24-5P	131585-25-6P

10/016850

131585-26-7P	131585-27-8P	131585-28-9P	131585-29-0P	131585-30-3P
131585-31-4P	131585-32-5P	131585-33-6P	131585-34-7P	131585-35-8P
131585-36-9P	131585-37-0P	131585-39-2P	131585-42-7P	131585-47-2P
131585-48-3P	131585-49-4P	131585-50-7P	131585-51-8P	131585-52-9P
131585-53-0P	131585-54-1P	131585-55-2P	131585-56-3P	131585-57-4P
131585-58-5P	131585-59-6P	131585-60-9P	131585-61-0P	131585-62-1P
131585-63-2P	131585-64-3P	131585-65-4P	131585-66-5P	131585-67-6P
131585-68-7P	131585-69-8P	131585-70-1P	131585-71-2P	131585-72-3P
131585-73-4P	131585-74-5P	131585-75-6P	131585-76-7P	131585-77-8P
131585-78-9P	131585-79-0P	131585-80-3P	131585-81-4P	131585-82-5P


(carbostyryl oxytocin receptor antagonists)

IT 131583-08-9P

(carbostyryl oxytocin receptor antagonists)

RN 131583-08-9 USPATFULL

CN Benzamide, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



=> file stnguide

10/016850

(FILE 'HOME' ENTERED AT 00:43:06 ON 30 SEP 2003)

FILE 'REGISTRY' ENTERED AT 00:43:28 ON 30 SEP 2003

L1 STRUCTURE uploaded
L2 50 S L1 SSS SAM
L3 1078 S L1 SSS FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 00:44:08 ON 30 SEP 2003

L4 12 S L3 AND ADRENERG?
L5 8 S L4 AND (LINK? OR COVALENT? OR CONJUGAT?)
L6 8 DUP REM L5 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 00:47:19 ON 30 SEP 2003

FILE 'STNGUIDE' ENTERED AT 01:05:00 ON 30 SEP 2003

FILE 'REGISTRY' ENTERED AT 01:05:09 ON 30 SEP 2003

L7 STRUCTURE uploaded
L8 0 S L7 SSS SAM
L9 0 S L7 SSS FULL

FILE 'STNGUIDE' ENTERED AT 01:06:48 ON 30 SEP 2003

FILE 'REGISTRY' ENTERED AT 01:10:52 ON 30 SEP 2003

L10 STRUCTURE uploaded
L11 50 S L10 SSS SAM
L12 1099 S L10 SSS FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 01:11:40 ON 30 SEP 2003

L13 8 S L12 AND (LINK? OR COVALENT? OR CONJUGAT?) AND ADRENERG?
L14 8 DUP REM L13 (0 DUPLICATES REMOVED)
L15 28 S L12 AND (LINK? OR COVALENT? OR CONJUGAT?)
L16 27 DUP REM L15 (1 DUPLICATE REMOVED)
L17 0 S L14 NOT L6
L18 8 S L16 AND ADRENERG?

FILE 'STNGUIDE' ENTERED AT 01:14:45 ON 30 SEP 2003

Delacroix

=> d 116 abs ibib kwic hitstr 1-27

L16 ANSWER 1 OF 27 USPATFULL on STN

AB The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:243617 USPATFULL

TITLE: Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation

INVENTOR(S): Sircar, Jagadish C., San Diego, CA, UNITED STATES
Richards, Mark L., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132808	A1	20020919
APPLICATION INFO.:	US 2002-90044	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275260P	20010312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1736	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


SUMM . . . causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-link immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators, . . .

DETD . . . some of the tested cell lines and previous Western blot results with the compounds, there is evidence to suggest a link between NF-.kappa.B inhibition and the action of the drugs. Breast cancer cells offer a good model for testing this phenomenon. . .

IT	459807-38-6P	459807-39-7P	459807-40-0P	459807-41-1P	
	459807-42-2P	459807-43-3P	459807-44-4P	459807-45-5P	
	459807-46-6P	459807-47-7P	459807-48-8P	459807-49-9P	459807-50-2P
	459807-51-3P	459807-52-4P	459807-53-5P	459807-54-6P	459807-55-7P
	459807-56-8P	459807-57-9P	459807-58-0P	459807-59-1P	459807-60-4P
	459807-61-5P	459807-62-6P	459807-63-7P	459807-64-8P	459807-65-9P
	459807-66-0P	459807-67-1P	459807-68-2P	459807-69-3P	459807-70-6P
	459807-71-7P	459807-72-8P	459807-73-9P	459807-74-0P	459807-75-1P
	459807-76-2P	459807-77-3P	459807-78-4P	459807-79-5P	459807-80-8P
	459807-81-9P	459807-82-0P	459807-83-1P	459807-84-2P	459807-85-3P
	459807-86-4P	459807-87-5P	459807-88-6P	459807-89-7P	459807-90-0P
	459807-91-1P	459807-92-2P	459807-93-3P	459807-94-4P	459807-95-5P
	459807-96-6P	459807-97-7P	459807-98-8P	459807-99-9P	459808-00-5P
	459808-01-6P	459808-02-7P	459808-03-8P	459808-04-9P	459808-05-0P
	459808-06-1P	459808-07-2P	459808-08-3P	459808-09-4P	459808-10-7P

459808-11-8P 459808-12-9P 459808-13-0P 459808-14-1P 459808-15-2P
 459808-16-3P 459808-17-4P 459808-18-5P 459808-19-6P 459808-20-9P
 459808-21-0P 459808-22-1P 459808-23-2P 459808-24-3P 459808-25-4P
 459808-26-5P 459808-27-6P 459808-28-7P 459808-29-8P 459808-30-1P
 459808-31-2P 459808-32-3P 459808-33-4P 459808-34-5P 459808-35-6P
 459808-36-7P 459808-37-8P 459808-38-9P 459808-39-0P 459808-40-3P
 459808-41-4P 459808-42-5P 459808-43-6P 459808-44-7P 459808-45-8P
 459808-46-9P 459808-47-0P 459808-48-1P 459808-49-2P 459808-50-5P
 459808-51-6P 459808-52-7P 459808-53-8P 459808-54-9P 459808-55-0P
 459808-56-1P 459808-57-2P 459808-58-3P 459808-59-4P 459808-60-7P
 459808-61-8P 459808-62-9P 459808-63-0P 459808-64-1P 459808-65-2P
 459808-66-3P 459808-67-4P 459808-68-5P 459808-69-6P 459808-70-9P
 459808-71-0P 459808-72-1P 459808-73-2P 459808-74-3P 459808-75-4P
 459808-76-5P 459808-77-6P 459808-78-7P 459808-79-8P 459808-80-1P
 459808-81-2P 459808-82-3P 459808-83-4P 459808-84-5P 459808-85-6P
 459808-86-7P 459808-87-8P 459808-88-9P 459808-89-0P 459808-90-3P
 459808-91-4P 459808-92-5P 459808-93-6P 459808-94-7P 459808-95-8P
 459808-96-9P 459808-97-0P 459808-98-1P 459808-99-2P 459809-00-8P
 459809-01-9P 459809-02-0P 459809-03-1P 459809-04-2P 459809-05-3P
 459809-06-4P 459809-07-5P 459809-08-6P 459809-09-7P 459809-10-0P
 459809-11-1P 459809-12-2P 459809-13-3P 459809-14-4P 459809-15-5P
 459809-16-6P 459809-17-7P 459809-18-8P 459809-19-9P 459809-20-2P
 (prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and
 analogs as IgE and cell proliferation inhibitors)

IT 459807-42-2P
 (prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and
 analogs as IgE and cell proliferation inhibitors)
 RN 459807-42-2 USPATFULL
 CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-[(methyltricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]phenyl]-1H-benzimidazol-5-yl]-(9CI) (CA INDEX
 NAME)



L16 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN
 AB N,N-Dimethyl-1-adamantamine-HF (2MAAHF) is a cryst. mol. species with a three-center covalent N-H-F bond; it can be recovered unchanged from aq. soln. The satd. soln. is a liq. pentahydrate; this quantity of H₂O is insufficient to form a clathrate cage around 2MAAHF. Incremental increase of H₂O content results in dramatic changes in the NMR spectrum of 2MAAHF. This behavior differs from that obsd. with the ionic salt 2MAAH⁺Cl⁻. The satd. soln. of 2MAAH⁺Cl⁻ contains 11.5 mol equiv. H₂O, the amt. required for formation of a clathrate cage about such cations, and essentially no change in the NMR spectrum takes place on diln. Even in dil. solns., the spectra of 2MAAHF and 2MAAH⁺Cl⁻ are not the same. The NMR spectral properties of 2MAAHF cannot be explained by effect of either F- or 2MAAH⁺ alone, but must result from the combined effects of both. This leads us to assume that 2MAAHF remains as an unionized mol. species in aq. soln.

ACCESSION NUMBER: 2002:98131 HCAPLUS
 DOCUMENT NUMBER: 137:62990
 TITLE: Hydrogen bonding. Part 79. FT-NMR study of hydration

of N,N-dimethyl-1-adamantamine-hydrogen fluoride and
 N,N-dimethyl-1-adamantylammonium chloride
 AUTHOR(S) : Benning, Nicole M.; Harmon, Kenneth M.
 CORPORATE SOURCE : Department of Chemistry, Oakland University,
 Rochester, MI, 48309, USA
 SOURCE : Journal of Molecular Structure (2002), 606(1-3),
 197-203
 CODEN: JMOSB4; ISSN: 0022-2860
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB N,N-Dimethyl-1-adamantamine-HF (2MAAHF) is a cryst. mol. species with a
 three-center covalent N-H-F bond; it can be recovered unchanged
 from aq. soln. The satd. soln. is a liq. pentahydrate; this quantity of.

IT Bond
 (covalent, three center N-H-F; hydrogen bonding and FT-NMR
 study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and
 N,N-dimethyl-1-adamantylammonium chloride)

IT 439610-54-5
 RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
 (hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
 adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
 chloride)


IT 439610-50-1 439610-51-2 439610-52-3
 RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical
 process); PRP (Properties); PYP (Physical process); FORM (Formation,
 nonpreparative); PROC (Process)
 (hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
 adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
 chloride)

IT 3727-95-5 7732-18-5, Water, properties 273720-80-2
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
 (Physical process); PROC (Process)
 (hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
 adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
 chloride)

IT 3717-40-6 439610-53-4
 RL: PRP (Properties)
 (hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
 adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
 chloride)

IT 439610-54-5
 RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
 (hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
 adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
 chloride)

RN 439610-54-5 HCAPLUS
 CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride,
 monohydrate (9CI) (CA INDEX NAME)



● HF

● H₂O


IT 439610-50-1 439610-51-2 439610-52-3

RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); FORM (Formation, nonpreparative); PROC (Process)

(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

RN 439610-50-1 HCPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride, hydrate (2:23) (9CI) (CA INDEX NAME)




● HCl

23/2 H₂O

RN 439610-51-2 HCPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, pentahydrate (9CI) (CA INDEX NAME)


10/016850



● HF

5 H₂O


RN 439610-52-3 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride,
undecahydrate (9CI) (CA INDEX NAME)



● HCl

11 H₂O

IT 3727-95-5 273720-80-2
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
(Physical process); PROC (Process)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-
adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium
chloride)
RN 3727-95-5 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride (9CI) (CA
INDEX NAME)




HCl

Delacroix


10/016850

RN 273720-80-2 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride (9CI) (CA INDEX NAME)




● HF

IT 3717-40-6 439610-53-4
RL: PRP (Properties)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)
RN 3717-40-6 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 439610-53-4 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, conjugate acid (9CI) (CA INDEX NAME)



● H⁺


REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN
AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is a mol. species which does not dissociate in aq. soln., and which contains a covalent three-center NHF bond. This compound forms three hydrates, a stoichiometric liq. pentahydrate, a reasonably stable cryst. trihydrate, and an ephemeral cryst. monohydrate. IR spectra and ab initio geometry optimization demonstrate that the monohydrate forms a dimeric cluster of Ci symmetry with a C2h planar (H2O.cndot.F)2 unit sandwiched between bound amine

10/016850

units. This structure contains 4HOHF, 2CHF, 4CHOH₂, and 2NHF hydrogen bonds. The assocn. energies of these bonds are estd. by MO methods, and the possible reasons for the extraordinary instability of the (H₂O.cndot.F)₂ unit relative to similar units in quaternary ammonium fluoride monohydrates are discussed.

ACCESSION NUMBER: 2002:943723 HCPLUS
DOCUMENT NUMBER: 138:262055
TITLE: Hydrogen bonding. Part 81. Infrared and molecular orbital study of the hydrates of N,N-dimethyl-1-adamantamine-hydrogen fluoride
AUTHOR(S): Harmon, Kenneth M.; Nicolla, Eranda; Benning, Nicole M.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309-4401, USA
SOURCE: Journal of Molecular Structure (2002), 642(1-3), 85-91
CODEN: JMOSEB4; ISSN: 0022-2860
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is a mol. species which does not dissociate in aq. soln., and which contains a covalent three-center NHF bond. This compd. forms three hydrates, a stoichiometric liq. pentahydrate, a reasonably stable cryst. trihydrate, and an ephemeral. . .
IT 439610-51-2 439610-54-5 502704-71-4
RL: PRP (Properties)
(IR and MO study of hydrogen bonding in hydrates of N,N-di-Me-1-adamantamine-hydrogen fluoride)
IT 439610-51-2 439610-54-5 502704-71-4
RL: PRP (Properties)
(IR and MO study of hydrogen bonding in hydrates of N,N-di-Me-1-adamantamine-hydrogen fluoride)
RN 439610-51-2 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, pentahydrate (9CI) (CA INDEX NAME)




● HF

5 H₂O

RN 439610-54-5 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, monohydrate (9CI) (CA INDEX NAME)

Delacroix


10/016850



● HF

● H₂O

RN 502704-71-4 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, trihydrate (9CI) (CA INDEX NAME)



● HF

3 H₂O

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 27 USPATFULL on STN

AB The present invention relates to the use of compounds capable of displacing tritiated cis-N-cyclohexyl-N-ethyl [3-(3-chloro-4-cyclohexylphenyl)-allyl]amine from its receptors for the preparation of pharmaceutical compositions intended to combat cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:75443 USPATFULL

TITLE: Use of amines to produce drugs for preventing tumor cell proliferation

INVENTOR(S): Breliere, Jean Claude, Montpellier, France
Ferrara, Pascual, Avignonet Lauragais, France
Lebouteiller, Christine, Pechabou, France
Paul, Raymond, Saint Gely du Fesc, France
Rosenfeld, Jorge, Baziege, France

PATENT ASSIGNEE(S): Van Broeck, Didier, Murviel les Montpellier, France
Sanofi-Synthelabo, Paris, France (non-U.S. corporation)

Delacroix

10/016850

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235791	B1	20010522
	WO 9804251		19980205
APPLICATION INFO.:	US 1999-230643		19990412 (9)
	WO 1997-FR1409		19970728
			19990412 PCT 371 date
			19990412 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-9531	19960729
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chang, Ceila	
LEGAL REPRESENTATIVE:	Alexander, Michael D.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1379	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM or RB and RC together form a --CH.dbd. bridge, and the bond with links it to the aromatic ring is a single bond and, in this case, A.sub.c represents a CH.sub.2 group and RA. . .

SUMM the carbonyl being linked to the oxygen and the bond connecting A.sub.c to the carbon bearing the side chain is a double bond, and, . . .

SUMM . . . from H, OH, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, halogen and cyano; V.sub.1 and V.sub.2 together form a double bond linked to an oxygen atom or alternatively a hydroxyimino radical N--OH, or alternatively are connected as an ethylenedioxy chain --O--CH.sub.2 --CH.sub.2. . .

IT 132173-04-7P 132173-06-9P 132173-12-7P 132186-55-1P 202720-04-5P
202720-06-7P 202720-08-9P 202720-09-0P 202720-10-3P
202720-11-4P 202720-12-5P 202720-13-6P 202720-14-7P
202720-15-8P 202720-16-9P 202720-17-0P 202720-18-1P 202720-19-2P
202720-20-5P 202720-21-6P 202720-22-7P 202720-23-8P 202720-24-9P
202720-25-0P 202720-26-1P 202720-27-2P 202720-28-3P 202720-29-4P
202720-30-7P 202720-31-8P 202720-32-9P 202720-33-0P 202720-34-1P
202720-35-2P 202720-36-3P 202720-37-4P 202720-38-5P 202720-39-6P
202720-40-9P 202720-41-0P 202720-42-1P 202720-43-2P
202720-44-3P 202720-45-4P 202720-46-5P

(prepn. of N-[(cyclohexylphenyl)alk(en)yl]piperidines and analogs as tumor cell proliferation inhibitors)


IT 202720-11-4P 202720-41-0P
(prepn. of N-[(cyclohexylphenyl)alk(en)yl]piperidines and analogs as tumor cell proliferation inhibitors)

RN 202720-11-4 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-amine, N-[3-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-, hydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Delacroix




● HCl

RN 202720-41-0 USPATFULL

CN Tricyclo[3.3.1.13,7]decane-1-amine, N-[3-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 5 OF 27 USPATFULL on STN

AB The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:8090 USPATFULL

TITLE: Therapeutic guanidines

INVENTOR(S): Goldin, Stanley M., Lexington, MA, United States
Fischer, James B., Cambridge, MA, United States
Knapp, Andrew Gannett, Salem, MA, United States
Reddy, N. Laxma, Malden, MA, United States
Berlove, David, Cambridge, MA, United States
Durant, Graham J., Cambridge, MA, United States
Katrakadda, Subbarao, Belmont, MA, United States
Hu, Lain-Yen, Bedford, MA, United States
Magar, Sharad, Somerville, MA, United States
Fan, Wenhong, Rockey Hill, CT, United States
Yost, Elizabeth, Waltham, MA, United States
Guo, Jun Qing, Waltham, MA, United States
PATENT ASSIGNEE(S): Cambridge NeuroScience, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6174924	B1	20010116
APPLICATION INFO.:	US 1995-462013		19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1995-US1536, filed on 3 Feb 1995 Continuation-in-part of Ser. No. US 1994-191793, filed on 3 Feb 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	O'Sullivan, Peter		
LEGAL REPRESENTATIVE:	Dike, Bronstein, Roberts & Cushman, LLP, Conlin, David G., Corless, Peter F.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4248		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
SUMM	. . . leading to a large and rapid increase in intracellular Ca.sup.2+. A subclass of non-NMDA receptors has been found to be linked to a Ca-permeable cation channel [Sommer, B., and Seuberg, P. H., Trends Pharmacol. Sci. 13:291-296 (1992)]. Although non-NMDA receptors are in most other instances linked to cation channels that largely exclude calcium, they can indirectly promote Ca.sup.2+ entry into neurons by depolarizing the cell membrane, .		
SUMM	. . . Non-NMDA receptors constitute a broad category of postsynaptic receptor sites which, as is the case for NMDA receptors, are directly linked to ion channels. Specifically, the receptor sites are physically part of specific ion channel proteins. Non-NMDA receptors have been broadly. . .		
SUMM	. . . NMDA antagonists may largely be the artifactual result of induction of hypothermia rather than due to direct inhibition of NMDA receptor-linked Ca entry into brain neurons [Buchan, A. et al., J. Neurosci., 11 (1991) 1049-1056]. In contrast, the competitive non-NMDA receptor. . .		
SUMM	. . . group as defined for R.sup.1 above; or R.sup.2 and R.sup.3 are taken together to form a substituted or unsubstituted alkylene linkage of from 2 to about 6 carbon atoms; and pharmaceutically acceptable salts thereof.		
SUMM	. . . the invention, also include those compounds wherein R.sup.2 and R.sup.3 are taken together to form a substituted or unsubstituted alkylene linkage of from 3 to about 6 carbon atoms, particularly compounds with an alkylene linkage of 3 carbon atoms as represented of the following Formula IV(B): ##STR11##		
SUMM	. . . t-butyl, iso-butyl, sec-butyl, pentyl, hexyl, heptyl, etc. Preferred alkenyl and alkynyl groups include those groups having one or more unsaturated linkages, preferably one or two unsaturated linkages and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms. Each of the terms. . . groups are generally more preferred. Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1. . . benzyloxy (i.e., C.sub.6 H.sub.5 CH.sub.2 O--) are preferred aralkoxy groups. Preferred thioalkyl groups include groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1. . .		
SUMM	. . . atoms or from 1 to about 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages		

and from 2 to about 12 carbon atoms or from 2 to about 6 carbon atoms; alkoxy groups such as those groups having one or more oxygen linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; thioalkyl groups such as those groups having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as . . .

SUMM Compounds of Formula IV where R.² and R.³ taken together form a substituted or unsubstituted alkylene linkage of from 2 to about 6 carbon atoms can be prepared as exemplified by the procedure disclosed in Example 8. . .

IT	104919-99-5P	155270-61-4P	167310-63-6P	167313-63-5P	169958-59-2P
	171764-75-3P	171764-76-4P	171764-77-5P	171764-78-6P	171764-79-7P
	171764-81-1P	171764-82-2P	171764-83-3P	171764-84-4P	171764-85-5P
	171764-86-6P	171764-87-7P	171764-88-8P	171764-89-9P	171764-90-2P
	171764-91-3P	171764-92-4P	171764-93-5P	171764-94-6P	171764-95-7P
	171764-96-8P	171764-97-9P	171764-98-0P	171764-99-1P	171765-00-7P
	171765-01-8P	171765-03-0P	171765-04-1P	171765-05-2P	171765-06-3P
	171765-07-4P	171765-08-5P	171765-09-6P	171765-10-9P	171765-12-1P
	171765-13-2P	171765-14-3P	171765-15-4P	171765-16-5P	171765-17-6P
	171765-18-7P	171765-19-8P	171765-20-1P	171765-21-2P	171765-22-3P
	171765-23-4P	171765-24-5P	171765-25-6P	171765-26-7P	171765-27-8P
	171765-28-9P	171765-29-0P	171765-30-3P	171765-31-4P	171765-32-5P
	171765-33-6P	171765-34-7P	171765-35-8P	171765-36-9P	171765-37-0P
	171765-38-1P	171765-39-2P	171765-40-5P	171765-41-6P	171765-42-7P
	171765-43-8P	171765-44-9P	171765-45-0P	171765-46-1P	171765-47-2P
	171765-48-3P	171765-49-4P	171765-50-7P	171765-51-8P	171765-52-9P
	171765-53-0P	171765-54-1P	171765-55-2P	171765-56-3P	171765-57-4P
	171765-58-5P	171765-59-6P	171765-60-9P	171765-61-0P	171765-62-1P
	171765-63-2P	171765-64-3P	171765-65-4P	171765-66-5P	171765-67-6P
	171765-68-7P	171765-69-8P	171765-70-1P	171765-71-2P	171765-72-3P
	171765-73-4P	171765-74-5P	171765-75-6P	171765-76-7P	171765-77-8P
	171765-78-9P	171765-79-0P	171765-80-3P	171765-81-4P	171765-82-5P
	171765-83-6P	171765-84-7P	171765-85-8P	171765-86-9P	171765-87-0P
	171765-88-1P	171765-89-2P	171765-90-5P	171765-91-6P	171765-92-7P
	171765-93-8P	171765-94-9P	171765-95-0P	171765-96-1P	171765-97-2P
	171765-98-3P	171765-99-4P	171766-00-0P	171766-01-1P	171766-02-2P
	171766-03-3P	171766-04-4P	171766-05-5P	171766-06-6P	171766-07-7P
	171766-08-8P	171766-09-9P	171766-10-2P	171766-11-3P	171766-12-4P
	171766-13-5P	171766-14-6P	171766-15-7P	171766-16-8P	171766-17-9P
	171766-18-0P	171766-19-1P	171766-20-4P	171766-21-5P	171766-22-6P
	171766-23-7P	171766-24-8P	171766-25-9P	171766-26-0P	171766-27-1P
	171766-28-2P	171766-29-3P	171766-30-6P	171766-31-7P	171766-32-8P
	171766-33-9P	171766-34-0P	171766-35-1P	171766-36-2P	171766-37-3P
	171766-38-4P	171766-39-5P	171766-40-8P	171766-41-9P	171766-42-0P
	171766-43-1P	171766-44-2P	171766-45-3P	171766-46-4P	171766-47-5P
	171766-48-6P	171766-49-7P	171766-50-0P	171766-51-1P	171766-52-2P
	171766-53-3P	171766-54-4P	171766-55-5P	171766-56-6P	171766-57-7P
	171766-58-8P	171766-59-9P	171766-60-2P	171766-61-3P	171766-62-4P
	171766-63-5P	171766-64-6P	171766-65-7P	171766-66-8P	171766-67-9P
	171766-68-0P	171766-69-1P	171766-70-4P	171766-71-5P	171766-72-6P
	171766-73-7P	171766-74-8P	171766-75-9P	171766-76-0P	171766-77-1P
	171766-78-2P	171766-79-3P	171766-80-6P	171766-81-7P	
	171766-82-8P	171766-83-9P	171766-84-0P	171766-85-1P	
	171766-86-2P	171766-87-3P	171766-88-4P	171766-89-5P	
	171766-90-8P	171766-91-9P	171766-92-0P	171766-93-1P	
	171766-94-2P	171766-95-3P	171766-96-4P	171766-97-5P	171766-98-6P
	171766-99-7P	171767-00-3P	171767-01-4P	171767-02-5P	171767-03-6P
	171767-04-7P	171767-05-8P	171767-06-9P		

10/016850

(prepn. of arylguanidines as glutamate release inhibitors)

IT 171767-07-0P 171767-08-1P 171767-09-2P 171767-10-5P 171767-11-6P
171767-12-7P 171767-13-8P 171767-14-9P 171767-15-0P 171767-16-1P
171767-17-2P 171767-18-3P 171767-19-4P 171767-20-7P 171767-21-8P
171767-22-9P 171767-23-0P 171767-24-1P 171767-25-2P 171767-26-3P
171767-27-4P 171767-28-5P 171767-29-6P 171767-30-9P 171767-31-0P
171767-32-1P 171767-33-2P 171767-34-3P 171767-35-4P 171767-36-5P
171767-37-6P 171767-38-7P 171767-39-8P 171767-40-1P 171767-41-2P
171767-42-3P 171767-43-4P 171767-44-5P 171767-45-6P 171767-46-7P
171767-47-8P 171767-48-9P 171767-49-0P 171767-50-3P 171767-51-4P
171767-52-5P 171767-53-6P 171767-54-7P 171767-55-8P 171767-56-9P
171767-57-0P 171767-58-1P 171767-59-2P 171767-60-5P 171767-61-6P
171767-62-7P 171767-63-8P 171767-64-9P 171767-65-0P 171767-66-1P
171767-67-2P 171767-68-3P 171767-69-4P 171767-70-7P 171767-71-8P
171767-72-9P 171767-73-0P 171767-74-1P 171767-75-2P 171767-76-3P
171767-77-4P 171767-78-5P 171767-79-6P 171767-80-9P 171767-81-0P
171767-82-1P 171767-83-2P 171767-84-3P 171767-85-4P 171767-86-5P
171767-87-6P 171767-88-7P 171767-89-8P 171767-90-1P 171767-91-2P
171767-92-3P 171767-93-4P 171767-94-5P 171767-95-6P 171767-96-7P
171767-97-8P 171767-98-9P 171767-99-0P 171768-00-6P 171768-01-7P
171768-02-8P 171768-03-9P 171768-04-0P 171768-05-1P 171768-06-2P
171768-07-3P 171768-08-4P 171768-09-5P 171768-10-8P 171768-11-9P
171768-12-0P 171768-13-1P 171768-14-2P 171768-15-3P 171768-16-4P
171768-17-5P 171768-18-6P 171768-19-7P 171768-20-0P 171768-21-1P
171768-22-2P 171768-23-3P 171768-24-4P 171768-25-5P 171768-26-6P
171768-27-7P 171768-28-8P 171768-29-9P 171768-30-2P 171768-31-3P
171768-32-4P 171768-33-5P 171768-34-6P 171768-35-7P 171768-36-8P
171768-37-9P 171768-38-0P 171768-39-1P 171768-40-4P 171768-41-5P
171768-52-8P 171768-53-9P 171768-54-0P 171864-64-5P
171864-65-6P 171864-66-7P 171864-67-8P 171864-68-9P 171864-69-0P

(prepn. of arylguanidines as glutamate release inhibitors)


IT 171766-82-8P 171766-83-9P 171766-90-8P

171766-91-9P 171768-52-8P 171768-53-9P

(prepn. of arylguanidines as glutamate release inhibitors)

RN 171766-82-8 USPATFULL

CN Guanidine, N'-1-anthracenyl-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI)
(CA INDEX NAME)




RN 171766-83-9 USPATFULL

CN Guanidine, N-1-anthracenyl-N,N'-dimethyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)


Delacroix

10/016850




RN 171766-90-8 USPATFULL

CN Guanidine, N-methyl-N'-1-phenanthrenyl-N-tricyclo[3.3.1.13,7]dec-1-yl-
(9CI) (CA INDEX NAME)




RN 171766-91-9 USPATFULL

CN Guanidine, N,N'-dimethyl-N-1-phenanthrenyl-N'-tricyclo[3.3.1.13,7]dec-1-yl-
(9CI) (CA INDEX NAME)




RN 171768-52-8 USPATFULL

CN Guanidine, N'-9H-fluoren-1-yl-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl-
(9CI) (CA INDEX NAME)



Delacroix

RN 171768-53-9 USPATFULL
 CN Guanidine, N-9H-fluoren-1-yl-N,N'-dimethyl-N'-tricyclo[3.3.1.13,7]dec-1-yl-
 (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4747 USPATFULL
 TITLE: Compounds having effects on serotonin-related systems
 INVENTOR(S): Audia, James E., Indianapolis, IN, United States
 Hibschnan, David J., Bargersville, IN, United States
 Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Nissen, Jeffrey S., Fishers, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 Wong, David T., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172073	B1	20010109
APPLICATION INFO.:	US 1998-49837		19980327 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789 Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lentz, Nelsen L.		
NUMBER OF CLAIMS:	8		

EXEMPLARY CLAIM:

1

LINE COUNT: 5343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 ethylene groups may be in the linker alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be linked in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-linked group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-linked fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . . .

IT	55581-45-8P	73889-11-9P	180156-51-8P	180156-53-0P	180156-54-1P
	180156-56-3P	180156-58-5P	180156-60-9P	180156-61-0P	180156-63-2P
	180156-65-4P	180156-67-6P	180156-69-8P	180156-71-2P	180156-73-4P
	180156-75-6P	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P
	180156-85-8P	180156-87-0P	180156-89-2P	180156-91-6P	180156-92-7P
	180156-94-9P	180156-96-1P	180156-98-3P	180157-00-0P	180157-02-2P
	180157-04-4P	180157-06-6P	180157-08-8P	180157-10-2P	180157-12-4P
	180157-14-6P	180157-16-8P	180157-18-0P	180157-20-4P	180157-22-6P
	180157-24-8P	180157-26-0P	180157-28-2P	180157-30-6P	180157-32-8P
	180157-34-0P	180157-36-2P	180157-38-4P	180157-40-8P	180157-42-0P
	180157-44-2P	180157-46-4P	180157-48-6P	180157-50-0P	180157-52-2P
	180157-54-4P	180157-56-6P	180157-58-8P	180157-60-2P	180157-62-4P
	180157-64-6P	180157-66-8P	180157-68-0P	180157-70-4P	180157-72-6P
	180157-74-8P	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P
	180157-84-0P	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P
	180157-94-2P	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
	180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
	180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
	180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
	180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
	180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
	180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
	180158-53-6P	180158-54-7P	180158-55-8P	180158-57-0P	180158-58-1P
	180158-59-2P	180158-60-5P	180158-61-6P	180158-63-8P	180158-65-0P
	180158-67-2P	180158-69-4P	180158-71-8P	180158-73-0P	180158-75-2P
	180158-77-4P	180158-79-6P	180158-81-0P	180158-83-2P	180158-85-4P
	180158-87-6P	180158-89-8P	180158-90-1P	180158-91-2P	180158-92-3P
	180158-93-4P	180158-94-5P	180158-95-6P	180158-96-7P	180158-97-8P
	180158-98-9P	180158-99-0P	180159-00-6P	180159-01-7P	180159-03-9P
	180159-05-1P	180159-07-3P	180159-09-5P	180159-11-9P	180159-12-0P
	180159-13-1P	180159-14-2P	180159-15-3P	180159-16-4P	180159-17-5P
	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P	180159-22-2P
	180159-23-3P	180159-24-4P	180159-25-5P	180159-26-6P	180159-27-7P
	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-35-7P
	180159-37-9P	180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P
	180159-47-1P	180159-49-3P	180159-51-7P	180159-53-9P	180159-55-1P
	180159-57-3P	180159-59-5P	180159-61-9P	180159-63-1P	180159-65-3P

10/016850

180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P
180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P
180159-87-9P 180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P
180159-95-9P 180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P
180160-00-3P 180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P
180160-05-8P 180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P
180160-10-5P 180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P
180160-15-0P 180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P
180160-20-7P 180160-21-8P 180160-22-9P 180160-23-0P 180160-24-1P
180160-25-2P

(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

IT 180160-26-3P 180160-27-4P 180160-28-5P 180160-29-6P 180160-30-9P
180160-31-0P 180160-32-1P 180160-33-2P 180160-34-3P
180160-35-4P 180160-36-5P 180271-36-7P


(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

IT 180158-52-5P 180160-33-2P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 180160-33-2 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Delacroix

L16 ANSWER 7 OF 27 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoyl amide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkyl acylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:41028 USPATFULL
 TITLE: Method of synergistic treatment for benign prostatic hyperplasia
 INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
 Stoner, Elizabeth, Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046183		20000404
APPLICATION INFO.:	US 1998-27105		19980220 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-428595, filed on 25 Apr 1995, now patented, Pat. No. US 5753641 which is a continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 20 Mar 1991, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Criares, Theodore J.
 LEGAL REPRESENTATIVE: Fitch, Catherine D.
 NUMBER OF CLAIMS: 2
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are linked together are cyclopentane, cyclohexane or a benzene ring; and

IT	98319-25-6P	98319-28-9P	98319-29-0P	103335-45-1P	103335-46-2P
	103335-48-4P	103335-56-4P	103335-57-5P	103497-68-3P	119169-78-7P
	119347-91-0P	119347-96-5P	119348-05-9P	133216-44-1P	134067-56-4P
	134067-64-4P	134217-16-6P	134217-17-7P	138715-91-0P	139229-87-1P
	139229-88-2P	139229-89-3P	139229-90-6P	139229-91-7P	139229-92-8P
	139229-93-9P	139229-94-0P	139229-95-1P	139229-97-3P	139230-03-8P
	139230-04-9P	139255-63-3P	139344-08-4P	139344-09-5P	139512-72-4P
	139512-73-5P	139512-75-7P	139512-76-8P	139512-77-9P	139512-78-0P
	139512-79-1P	139512-80-4P	139523-47-0P	139539-84-7P	139755-31-0P

10/016850

144879-06-1P 144879-08-3P 144879-10-7P 144879-16-3P 144879-17-4P
144879-18-5P 144879-21-0P 144879-25-4P 144879-27-6P 144879-29-8P
144879-32-3P 144879-33-4P 144879-34-5P 144879-35-6P 144879-36-7P
144879-37-8P 144879-38-9P 144879-39-0P 144879-40-3P 144879-41-4P
144879-48-1P 144879-50-5P 144879-55-0P 144879-60-7P 145191-61-3P
146032-67-9P 146032-69-1P 146057-96-7P 146142-97-4P
146143-98-8P
(prepn. of)


IT 146032-67-9P

(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 27 HCPLUS COPYRIGHT 2003 ACS on STN

AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is not a tertiary ammonium salt. It is a highly cryst. mol. complex whose IR spectrum demonstrates the presence of covalent type three-center N-H-F bonds. The compd. is obtained from ethanol-water soln., and FT-NMR spectra indicate that it is stable in aq. soln. An ab initio MO study of this and potentially similar tertiary amine-hydrogen fluoride complexes suggests a value of about -18 kcal mol-1 for the formation of N-H-F bond, and in addn. predicts that secondary C-H..cntdot..cntdot..cntdot.F hydrogens bonding by .beta.-hydrogens of the amine may be present in such compds.

ACCESSION NUMBER: 2000:220952 HCPLUS

DOCUMENT NUMBER: 133:30471

TITLE: Hydrogen bonding. Part 73. IR, NMR, and ab initio molecular orbital study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a crystalline, H2O stable compound with a three-center N-H-F bond

AUTHOR(S): Harmon, K. M.; Webb, A. C.

CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, USA

SOURCE: Journal of Molecular Structure (2000), 522, 79-86

CODEN: JMOB4; ISSN: 0022-2860

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

Delacroix

10/016850

AB . . . is not a tertiary ammonium salt. It is a highly cryst. mol. complex whose IR spectrum demonstrates the presence of covalent type three-center N-H-F bonds. The compd. is obtained from ethanol-water soln., and FT-NMR spectra indicate that it is stable in. . .

IT 273720-80-2

RL: PRP (Properties)

(IR, NMR, and ab initio MO study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a cryst., H₂O stable compd. with a three-center N-H-F bond)


IT 273720-80-2

RL: PRP (Properties)

(IR, NMR, and ab initio MO study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a cryst., H₂O stable compd. with a three-center N-H-F bond)

RN 273720-80-2 HCPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride (9CI) (CA INDEX NAME)



④ HF

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 27 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:54885 USPATFULL

TITLE: Method of treatment for benign prostatic hyperplasia

INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States

Stoner, Elizabeth, Westfield, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

Delacroix

10/016850

PATENT INFORMATION: US 5753641 19980519
APPLICATION INFO.: US 1995-428595 19950425 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 10 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Fitch, Catherine D., Nicholson, William H.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 5371


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are linked together are cyclopentane, cyclohexane or a benzene ring; and

IT	98319-25-6P	98319-28-9P	98319-29-0P	103335-45-1P	103335-46-2P
	103335-48-4P	103335-56-4P	103335-57-5P	103497-68-3P	119169-78-7P
	119347-91-0P	119347-96-5P	119348-05-9P	133216-44-1P	134067-56-4P
	134067-64-4P	134217-16-6P	134217-17-7P	138715-91-0P	139229-87-1P
	139229-88-2P	139229-89-3P	139229-90-6P	139229-91-7P	139229-92-8P
	139229-93-9P	139229-94-0P	139229-95-1P	139229-97-3P	139230-03-8P
	139230-04-9P	139255-63-3P	139344-08-4P	139344-09-5P	139512-72-4P
	139512-73-5P	139512-75-7P	139512-76-8P	139512-77-9P	139512-78-0P
	139512-79-1P	139512-80-4P	139523-47-0P	139539-84-7P	139755-31-0P
	144879-06-1P	144879-08-3P	144879-10-7P	144879-16-3P	144879-17-4P
	144879-18-5P	144879-21-0P	144879-25-4P	144879-27-6P	144879-29-8P
	144879-32-3P	144879-33-4P	144879-34-5P	144879-35-6P	144879-36-7P
	144879-37-8P	144879-38-9P	144879-39-0P	144879-40-3P	144879-41-4P
	144879-48-1P	144879-50-5P	144879-55-0P	144879-60-7P	145191-61-3P
	146032-67-9P	146032-69-1P	146057-96-7P	146142-97-4P	
	146143-98-8P (prepn. of)				
IT	146032-67-9P (prepn. of)				
RN	146032-67-9 USPATFULL				
CN	1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

Delacroix



L16 ANSWER 10 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1._{sub}A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:42357 USPATFULL
 TITLE: Compounds having effects on serotonin-related systems
 INVENTOR(S): Hibscher, David J., Bargersville, IN, United States
 Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5741789 19980421
 APPLICATION INFO.: US 1995-467434 19950606 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed
 on 17 Jan 1995, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Kifle, Bruck
 LEGAL REPRESENTATIVE: Palmberg, Arleen, Boone, David E.
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5902
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the linker alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .
 SUMM It may be noted again that bulky R._{sup}3 groups such as

dibenzocycloheptene or naphthyl may be linked in any reasonable orientation, as may substituent parts of the R.^{sup.3} group such as piperazinonyl.

SUMM The spiro-linked group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-linked fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally linked by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT	180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
	180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
	180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
	180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
	180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
	180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
	180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
	180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
	180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
	180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
	180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
	180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
	180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
	180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
	180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
	180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
	180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
	180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
	180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
	180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
	180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
	180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
	180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
	180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
	180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
	180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P
	180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
	180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
	180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
	180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
	180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
	180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P
	180159-96-0P	180159-97-1P	180159-98-2P	180159-99-3P	180160-00-3P
	180160-01-4P	180160-02-5P	180160-03-6P	180160-04-7P	180160-05-8P
	180160-06-9P	180160-07-0P	180160-08-1P	180160-09-2P	180160-10-5P
	180160-11-6P	180160-12-7P	180160-13-8P	180160-14-9P	180160-15-0P
	180160-16-1P	180160-17-2P	180160-18-3P	180160-19-4P	180160-20-7P
	180160-21-8P	180271-36-7P	185255-45-2P	185255-47-4P	185255-49-6P
	185255-51-0P	185255-53-2P	185255-55-4P	185255-67-8P	185255-71-4P
	185255-73-6P	190785-69-4P	190786-32-4P	190786-36-8P	190788-23-9P

(prepn. of heterocycloloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)


IT 180158-52-5P

(prepn. of heterocycloloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L16 ANSWER 11 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

97:38539 USPATFULL

TITLE:

Compounds having effects on serotonin-related systems

INVENTOR(S):

Audia, James E., Indianapolis, IN, United States

Hibschman, David J., Bargersville, IN, United States

Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Nissen, Jeffrey S., Fishers, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

Wong, David T., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5627196 19970506

APPLICATION INFO.: US 1995-468948 19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Bottino, Anthony
 LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
 NUMBER OF CLAIMS: 56
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The **spiro-linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a **spiro-linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . . .

IT	180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
	180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
	180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
	180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
	180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
	180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
	180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
	180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
	180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
	180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
	180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
	180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
	180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
	180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
	180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
	180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
	180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
	180158-49-0P	180158-50-3P	180158-51-4P	180158-52-5P	
	180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
	180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
	180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
	180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
	180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
	180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
	180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
	180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
	180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P

180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P
180159-96-0P	180159-97-1P	180159-98-2P	180159-99-3P	180160-00-3P
180160-01-4P	180160-02-5P	180160-03-6P	180160-04-7P	180160-05-8P
180160-06-9P	180160-07-0P	180160-08-1P	180160-09-2P	180160-10-5P
180160-11-6P	180160-12-7P	180160-13-8P	180160-14-9P	180160-15-0P
180160-16-1P	180160-17-2P	180160-18-3P	180160-19-4P	180160-20-7P
180160-21-8P	180271-36-7P	185255-45-2P	185255-47-4P	185255-49-6P
185255-51-0P	185255-53-2P	185255-55-4P	185255-67-8P	185255-71-4P
185255-73-6P	190785-69-4P	190786-32-4P	190786-36-8P	190788-23-9P

(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and
reuptake inhibitors)


IT 180158-52-5P

(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and
reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



© HCl

L16 ANSWER 12 OF 27 HCPLUS COPYRIGHT 2003 ACS on STN

AB New diacrylate monomers for cyclopolymer. were synthesized from the reaction of Et .alpha.-chloromethylacrylate (ECMA) and t-Bu .alpha.-bromomethylacrylate (TBBBr) with aniline, adamantyl amine, t-Bu amine, cyanamide, and 4-tetradecyl aniline in yields of ca. 50-70%. Bulk and soln. polymers. with azobisisobutyronitrile (AIBN) at 60-85.degree.C gave sol. cyclopolymers with Mn and Mw ranging from 10,000-30,000 and 12,000-40,000, resp. The ECMA-cyanamide deriv. only gave crosslinked polymers. ¹H and ¹³C soln. NMR indicated high cyclization efficiency (>93%). A prototype NLO polymer was synthesized from the reaction of the TBBBr-aniline cyclopolymer with tetracyanoethylene. The p-hydroxyaniline deriv. of ECMA was synthesized and used for further derivatizations; for example, the benzoate ester was made and polymd. (Mn = 21,260 and Mw = 40,317). The ester groups of the TBBBr-aniline polymer were hydrolyzed completely to give a polymer with both acid and base moieties. DSC thermograms showed glass transitions of 132.degree.C for the ECMA-aniline deriv., 1992.degree.C for the ECMA-adamantyl deriv., 53.degree.C for the

TBBr-tetradecylaniline deriv., and 120.degree.C for the ECMA-p-benzoylaniline deriv. The ECMA-t-Bu amine polymer showed no obvious Tg.

ACCESSION NUMBER: 1997:434444 HCPLUS
 DOCUMENT NUMBER: 127:162218
 TITLE: Cyclopolymerization of amine-linked diacrylate monomers
 AUTHOR(S): Avci, Duygu; Haynes, Camille; Mathias, Lon J.
 CORPORATE SOURCE: Chem. Dep., Bogazici Univ., Istanbul, 80815, Turk.
 SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1997), 35(10), 2111-2121
 CODEN: JPACEC; ISSN: 0887-624X
 PUBLISHER: Wiley
 DOCUMENT TYPE: Journal
 LANGUAGE: English

TI Cyclopolymerization of amine-linked diacrylate monomers
 ST cyclopolymer amine linked diacrylate; nonlinear optical material acrylic cyclopolymer
 IT Glass transition temperature (cyclopolymer. and properties of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT Solubility (cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT Polymerization (cyclopolymer.; cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT IR spectra
 NMR (nuclear magnetic resonance)
 Nonlinear optical materials (of amine-linked monomers and cyclopolymers from them)
 IT Solvent effect (on cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT 193527-64-9P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (attempted cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT 193527-67-2P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (cyclopolymer; cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT 670-54-2DP, Tetracyanoethylene, reaction products with acrylic cyclopolymer 193527-61-6P 193527-62-7P 193527-63-8P 193527-65-0P 193527-66-1P 193527-67-2DP, reaction products with tetracyanoethylene or hydrolyzed products 193527-68-3P 193527-69-4P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (cyclopolymer; cyclopolymer. of amine-linked diacrylate monomers and prep. of nonlinear optical materials)
 IT 193527-71-8P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate in monomer prep.; cyclopolymer. of amine-linked diacrylate monomers)
 IT 193527-52-5P 193527-53-6P 193527-54-7P 193527-55-8P 193527-56-9P 193527-57-0P 193527-58-1P 193527-59-2P

10/016850

193527-60-5P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; cyclopolymer. of amine-linked diacrylate monomers)

IT 62-53-3, Benzenamine, reactions 75-64-9, reactions 98-88-4, Benzoyl chloride 123-30-8, p-Hydroxyaniline 420-04-2, Cyanamide 720-98-9, 4-Benzoyloxyaniline 768-94-5, 1-Adamantylamine 17435-77-7, Ethyl .alpha.-chloromethylacrylate 53913-96-5, tert-Butyl .alpha.-bromomethylacrylate 91323-12-5, 4-Tetradecylaniline

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant in monomer prepn.; cyclopolymer. of amine-linked diacrylate monomers)


IT 193527-62-7P 193527-68-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(cyclopolymer; cyclopolymer. of amine-linked diacrylate monomers and prepn. of nonlinear optical materials)

RN 193527-62-7 HCAPLUS

CN 2-Propenoic acid, 2,2'-(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)bis-, diethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 193527-53-6
CMF C22 H33 N O4




RN 193527-68-3 HCAPLUS

CN 2-Propenoic acid, 2,2'-(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)bis-, bis(1,1-dimethylethyl) ester, homopolymer (9CI) (CA INDEX NAME)

CM 1


CRN 193527-59-2
CMF C26 H41 N O4




Delacroix

10/016850

IT 193527-53-6P 193527-59-2P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(monomer; cyclopolymer. of amine-linked diacrylate monomers)
RN 193527-53-6 HCPLUS
CN 2-Propenoic acid, 2,2'-(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 193527-59-2 HCPLUS
CN 2-Propenoic acid, 2,2'-(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 sub A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:106493 USPATFULL
TITLE: Compounds having effects on serotonin-related systems
INVENTOR(S): Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

Delacroix

PATENT INFORMATION: US 5576321 19961119
 APPLICATION INFO.: US 1995-468900 19950606 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed
 on 17 Jan 1995, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Bottino, Anthony
 LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The **spiro-linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a **spiro-linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT	55581-45-8P	73889-11-9P	180156-51-8P	180156-54-1P	180156-56-3P
	180156-60-9P	180156-61-0P	180156-63-2P	180156-67-6P	180156-69-8P
	180156-73-4P	180156-75-6P	180156-77-8P	180156-79-0P	180156-81-4P
	180156-83-6P	180156-85-8P	180156-87-0P	180156-89-2P	180156-91-6P
	180156-92-7P	180156-94-9P	180156-96-1P	180156-98-3P	180157-00-0P
	180157-02-2P	180157-04-4P	180157-06-6P	180157-08-8P	180157-10-2P
	180157-12-4P	180157-14-6P	180157-16-8P	180157-18-0P	180157-20-4P
	180157-22-6P	180157-24-8P	180157-26-0P	180157-28-2P	180157-30-6P
	180157-34-0P	180157-36-2P	180157-38-4P	180157-40-8P	180157-42-0P
	180157-44-2P	180157-46-4P	180157-50-0P	180157-52-2P	180157-54-4P
	180157-56-6P	180157-58-8P	180157-60-2P	180157-62-4P	180157-64-6P
	180157-66-8P	180157-68-0P	180157-70-4P	180157-72-6P	180157-74-8P
	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-02-5P
	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P	180158-12-7P
	180158-15-0P	180158-17-2P	180158-19-4P	180158-22-9P	180158-24-1P
	180158-26-3P	180158-28-5P	180158-30-9P	180158-32-1P	180158-34-3P
	180158-36-5P	180158-38-7P	180158-39-8P	180158-40-1P	180158-41-2P
	180158-42-3P	180158-43-4P	180158-44-5P	180158-45-6P	180158-46-7P
	180158-47-8P	180158-48-9P	180158-49-0P	180158-50-3P	180158-51-4P
	180158-52-5P	180158-53-6P	180158-54-7P	180158-55-8P	
	180158-57-0P	180158-58-1P	180158-59-2P	180158-60-5P	180158-61-6P
	180158-65-0P	180158-67-2P	180158-69-4P	180158-71-8P	180158-73-0P
	180158-75-2P	180158-77-4P	180158-79-6P	180158-81-0P	180158-83-2P
	180158-85-4P	180158-87-6P	180158-89-8P	180158-90-1P	180158-91-2P
	180158-92-3P	180158-93-4P	180158-94-5P	180158-97-8P	180158-98-9P
	180159-01-7P	180159-03-9P	180159-07-3P	180159-09-5P	180159-11-9P

10/016850

180159-12-0P	180159-13-1P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-24-4P	180159-25-5P	180159-26-6P
180159-27-7P	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P
180159-34-6P	180159-35-7P	180159-37-9P	180159-39-1P	180159-41-5P
180159-43-7P	180159-45-9P	180159-47-1P	180159-49-3P	180159-51-7P
180159-53-9P	180159-55-1P	180159-57-3P	180159-59-5P	180159-63-1P
180159-65-3P	180159-67-5P	180159-69-7P	180159-71-1P	180159-73-3P
180159-75-5P	180159-77-7P	180159-79-9P	180159-81-3P	180159-83-5P
180159-84-6P	180159-85-7P	180159-87-9P	180159-89-1P	180159-91-5P
180159-93-7P	180159-94-8P	180159-95-9P	180159-96-0P	180159-97-1P
180159-98-2P	180159-99-3P	180160-00-3P	180160-01-4P	180160-02-5P
180160-03-6P	180160-04-7P	180160-05-8P	180160-06-9P	180160-07-0P
180160-08-1P	180160-09-2P	180160-10-5P	180160-11-6P	180160-12-7P
180160-13-8P	180160-14-9P	180160-15-0P	180160-16-1P	180160-17-2P
180160-18-3P	180160-19-4P	180160-20-7P	180160-22-9P	180160-23-0P
180160-24-1P	180160-25-2P	180160-26-3P	180160-27-4P	180160-28-5P
180160-29-6P	180160-30-9P	180160-31-0P	180160-32-1P	
180160-33-2P	180160-34-3P	180160-35-4P	180160-36-5P	
180271-36-7P	185255-45-2P			

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and
analogs as 5-HT1A receptor ligands)


IT 180158-52-5P 180160-33-2P

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and
analogs as 5-HT1A receptor ligands)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 180160-33-2 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Delacroix



L16 ANSWER 14 OF 27 USPATFULL on STN

AB There are provided a catalyst, a method for making this catalyst, and a process for using this catalyst in the alkylation of an isoparaffin with an olefin to provide an alkylate. The catalyst may be made from an as-synthesized material which, upon calcination, is capable of generating zeolites designated MCM-22. The as-synthesized material is then combined with a binder material, such as alumina, by an extrusion process. The uncalcined bound material may then be ammonium exchanged, followed by a calcination treatment. The as-synthesized material may also be swollen with a suitable swelling agent, such as a cetyltrimethylammonium compound, prior to the binding process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:41398 USPATFULL
 TITLE: Catalyst and process for isoparaffin-olefin alkylation
 INVENTOR(S): Chu, Cynthia T.-W., Moorestown, NJ, United States
 Husain, Altaf, Marlton, NJ, United States
 Keville, Kathleen M., Beaumont, TX, United States
 Lissy, Daria N., Glen Mills, PA, United States
 PATENT ASSIGNEE(S): Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5516962		19960514
APPLICATION INFO.:	US 1994-283928		19940801 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-42907, filed on 5 Apr 1993, now patented, Pat. No. US 5354718		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Pal, Asok
 LEGAL REPRESENTATIVE: McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 1329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


SUMM . . . used in this extrusion process usually includes a substantial amount of chemically bound water in the form of hydroxyl groups covalently bonded to aluminum atoms.

SUMM . . . strength by a condensation reaction, whereby hydroxyl groups associated with aluminum atoms in the binder react to form Al --O--Al linkages and to liberate water.

IT 108-91-8, Aminocyclohexane, reactions 111-49-9 505-66-8,
 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,

10/016850

Azacyclooctane 5452-35-7, Aminocycloheptane 46244-96-6
116355-70-5
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)
IT 46244-96-6
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)
RN 46244-96-6 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX
NAME)



L16 ANSWER 15 OF 27 USPATFULL on STN

AB There is provided a process for converting organic compounds using a catalyst comprising a pillared, layered crystalline oxide material. This material may be prepared by intercepting a swellable layered oxide before calcination. The intercepted material is swollen and pillared. If the material is not intercepted in this manner, it is transformed into a zeolite by calcination. The pillared material may have a large degree of catalytic activity, and it may have rather porous layers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:100052 USPATFULL

TITLE: Organic conversion with a catalyst comprising a crystalline pillared oxide material

INVENTOR(S): Kresge, Charles T., West Chester, PA, United States
Roth, Wieslaw J., Sewell, NJ, United States
Simmons, Kenneth G., Williamstown, NJ, United States
Vartuli, James C., West Chester, NJ, United States

PATENT ASSIGNEE(S): Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5364999		19941115
APPLICATION INFO.:	US 1993-28440		19930309 (8)
DISCLAIMER DATE:	20100727		
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-811384, filed on 20 Dec 1991, now patented, Pat. No. US 5229341 which is a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned, said Ser. No. US -811384 which is a continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned Ser. No. Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pal, Asok		
ASSISTANT EXAMINER:	Achutamurthy, P.		
LEGAL REPRESENTATIVE:	McKillop, Alexander J., Santini, Dennis P., Kenehan,		

Delacroix

Jr., Edward F.

NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 1379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


SUMM . . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-linked with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-linking agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross linking agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .

IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8,
 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,
 Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6**
 116355-70-5
 (directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

IT **46244-96-6**
 (directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 16 OF 27 USPATFULL on STN

AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.A is ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:91061 USPATFULL
 TITLE: Carbostyryl oxytocin receptor antagonists
 INVENTOR(S): Freidinger, Roger M., Lansdale, PA, United States
 Pawluczyk, Joseph M., Warminster, PA, United States
 Pettibone, Douglas J., Shalfont, PA, United States
 Williams, Peter D., Harleysville, PA, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5356904		19941018
APPLICATION INFO.:	US 1992-957491		19921007 (7)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Cintins, Marianne M.
 ASSISTANT EXAMINER: Travers, Russell
 LEGAL REPRESENTATIVE: Appollina, Mary A., DiPrima, Joseph F.
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7213
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrlates and cross-linked or amphipathic block copolymers of hydrogels.


IT	131582-88-2P	131582-89-3P	131582-90-6P	131582-91-7P	131582-97-3P
	131582-99-5P	131583-01-2P	131583-04-5P	131583-05-6P	131583-06-7P
	131583-07-8P	131583-08-9P	131583-09-0P	131583-10-3P	
	131583-11-4P	131583-13-6P	131583-14-7P	131583-15-8P	131583-17-0P
	131583-18-1P	131583-19-2P	131583-20-5P	131583-21-6P	131583-23-8P
	131583-24-9P	131583-26-1P	131583-27-2P	131583-28-3P	131583-29-4P
	131583-30-7P	131583-31-8P	131583-33-0P	131583-34-1P	131583-35-2P
	131583-36-3P	131583-37-4P	131583-38-5P	131583-39-6P	131583-40-9P
	131583-41-0P	131583-42-1P	131583-43-2P	131583-44-3P	131583-45-4P
	131583-46-5P	131583-49-8P	131583-50-1P	131583-51-2P	131583-52-3P
	131583-53-4P	131583-57-8P	131583-58-9P	131583-60-3P	131583-61-4P
	131583-63-6P	131583-64-7P	131583-65-8P	131583-66-9P	131583-67-0P
	131583-71-6P	131583-72-7P	131583-74-9P	131583-75-0P	131583-76-1P
	131583-77-2P	131583-79-4P	131583-81-8P	131583-83-0P	131583-84-1P
	131583-87-4P	131583-88-5P	131583-89-6P	131583-90-9P	131583-91-0P
	131583-92-1P	131583-93-2P	131583-95-4P	131583-96-5P	131583-97-6P
	131583-98-7P	131583-99-8P	131584-01-5P	131584-02-6P	131584-03-7P
	131584-04-8P	131584-05-9P	131584-07-1P	131584-09-3P	131584-11-7P
	131584-12-8P	131584-13-9P	131584-14-0P	131584-15-1P	131584-16-2P
	131584-17-3P	131584-18-4P	131584-19-5P	131584-20-8P	131584-21-9P
	131584-22-0P	131584-23-1P	131584-24-2P	131584-25-3P	131584-26-4P
	131584-27-5P	131584-28-6P	131584-29-7P	131584-30-0P	131584-33-3P
	131584-36-6P	131584-37-7P	131584-38-8P	131584-40-2P	131584-41-3P
	131584-42-4P	131584-43-5P	131584-44-6P	131584-45-7P	131584-46-8P
	131584-47-9P	131584-48-0P	131584-49-1P	131584-50-4P	131584-51-5P
	131584-52-6P	131584-53-7P	131584-54-8P	131584-55-9P	131584-56-0P
	131584-57-1P	131584-58-2P	131584-59-3P	131584-60-6P	131584-61-7P
	131584-62-8P	131584-63-9P	131584-64-0P	131584-65-1P	131584-66-2P
	131584-67-3P	131584-68-4P	131584-69-5P	131584-70-8P	131584-71-9P
	131584-73-1P	131584-74-2P	131584-76-4P	131584-77-5P	131584-78-6P
	131584-79-7P	131584-80-0P	131584-81-1P	131584-82-2P	131584-83-3P
	131584-85-5P	131584-87-7P	131584-88-8P	131584-89-9P	131584-90-2P
	131584-92-4P	131584-93-5P	131584-94-6P	131584-95-7P	131584-98-0P
	131584-99-1P	131585-00-7P	131585-01-8P	131585-02-9P	131585-03-0P
	131585-04-1P	131585-05-2P	131585-06-3P	131585-07-4P	131585-08-5P
	131585-09-6P	131585-10-9P	131585-11-0P	131585-12-1P	131585-13-2P
	131585-14-3P	131585-15-4P	131585-16-5P	131585-17-6P	131585-18-7P
	131585-19-8P	131585-22-3P	131585-23-4P	131585-24-5P	131585-25-6P
	131585-26-7P	131585-27-8P	131585-28-9P	131585-29-0P	131585-30-3P
	131585-31-4P	131585-32-5P	131585-33-6P	131585-34-7P	131585-35-8P
	131585-36-9P	131585-37-0P	131585-39-2P	131585-42-7P	131585-47-2P
	131585-48-3P	131585-49-4P	131585-50-7P	131585-51-8P	131585-52-9P
	131585-53-0P	131585-54-1P	131585-55-2P	131585-56-3P	131585-57-4P
	131585-58-5P	131585-59-6P	131585-60-9P	131585-61-0P	131585-62-1P
	131585-63-2P	131585-64-3P	131585-65-4P	131585-66-5P	131585-67-6P

131585-68-7P 131585-69-8P 131585-70-1P 131585-71-2P 131585-72-3P
 131585-73-4P 131585-74-5P 131585-75-6P 131585-76-7P 131585-77-8P
 131585-78-9P 131585-79-0P 131585-80-3P 131585-81-4P 131585-82-5P
 (carbostyryl oxytocin receptor antagonists)

IT 131583-08-9P
 (carbostyryl oxytocin receptor antagonists)

RN 131583-08-9 USPATFULL

CN Benzamide, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



L16 ANSWER 17 OF 27 USPATFULL on STN

AB There are provided a catalyst, a method for making this catalyst, and a process for using this catalyst in the alkylation of an isoparaffin with an olefin to provide an alkylate. The catalyst may be made from an as-synthesized material which, upon calcination, is capable of generating zeolites designated MCM-22. The as-synthesized material is then combined with a binder material, such as alumina, by an extrusion process. The uncalcined bound material may then be ammonium exchanged, followed by a calcination treatment. The as-synthesized material may also be swollen with a suitable swelling agent, such as a cetyltrimethylammonium compound, prior to the binding process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

94:88661 USPATFULL

TITLE:

Catalyst and process for isoparaffin-olefin alkylation

INVENTOR(S):

Chu, Cynthia T-W., Moorestown, NJ, United States

Husain, Altaf, Marlton, NJ, United States

Keville, Kathleen M., Beaumont, TX, United States

Lissy, Daria N., Glen Mills, PA, United States

PATENT ASSIGNEE(S):

Mobil Oil Corporation, Fairfax, VA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5354718 19941011

APPLICATION INFO.: US 1993-42907 19930405 (8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Dees, Carl F.

LEGAL REPRESENTATIVE: McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1,17

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 1293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . used in this extrusion process usually includes a substantial amount of chemically bound water in the form of hydroxyl groups covalently bonded to aluminum atoms.

SUMM . . . crush strength by a condensation reaction, whereby hydroxyl groups associated with aluminum atoms in the binder react to form Al-O-Al linkages and to liberate water.

IT 108-91-8, Aminocyclohexane, reactions 111-49-9 505-66-8,
1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,
Azacyclooctane 5452-35-7, Aminocycloheptane 46244-96-6
116355-70-5


(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)

IT 46244-96-6

(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 18 OF 27 HCPLUS COPYRIGHT 2003 ACS on STN

AB The halide and hydroxide salts of the N,N,N-trimethyl-1-adamantylammonium ion have hydration behaviors which are different from the common patterns shown by all other quaternary ammonium ion halide and hydroxide salts we have studied. These differences include formation of higher iodide and bromide hydrates, failure to form halide monohydrates, and the existence of unusual mol. ions with three-center covalent hydrogen bonding in the lower fluoride and hydroxide hydrates. The ¹H NMR spectrum of N,N,N-trimethyl-1-adamantylammonium ion is not consistent with that expected from application of conventional chem. shift rules. Comparison with the model compds. trimethyl-i-pentylammonium and tetra-i-pentylammonium ions, which have similar C-H arrangements but lack the tricyclic cage, demonstrate that through-cage interactions spread pos. charge over the whole structure of the N,N,N-trimethyl-1-adamantylammonium ion. The diffusely charged nature of the ion is correlated with the obsd. anomalous hydration behavior of its salts.

ACCESSION NUMBER: 1995:120168 HCPLUS

DOCUMENT NUMBER: 122:9373

TITLE: Hydrogen bonding. Part 59. NMR study of N,N,N-trimethyl-1-adamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions; an explanation for the anomalous hydration behavior of N,N,N-trimethyl-1-adamantylammonium ion salts

AUTHOR(S): Harmon, Kenneth M.; Bulgarella, Jennifer A.

CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309, USA

SOURCE: Journal of Molecular Structure (1994), 326(1-3), 157-62

CODEN: JMOSEB4; ISSN: 0022-2860

DOCUMENT TYPE: Journal

LANGUAGE: English

10/016850

AB . . . of higher iodide and bromide hydrates, failure to form halide monohydrates, and the existence of unusual mol. ions with three-center covalent hydrogen bonding in the lower fluoride and hydroxide hydrates. The ^1H NMR spectrum of N,N,N-trimethyl-1-adamantylammonium ion is not consistent with. . .


IT 37841-17-1P, Tetraisopentylammonium 46244-96-6P 114328-82-4P
159389-92-1P, Trimethylisopentylammonium iodide
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (NMR of trimethyladamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions)

IT 3717-61-1, 1-Adamantyltrimethylammonium iodide 53075-09-5
, N,N,N-Trimethyl-1-adamantylammonium hydroxide 128346-46-3
138764-52-0 151299-37-5
RL: PEP (Physical, engineering or chemical process); PROC (Process) (anomalous hydration behavior of)

IT 46244-96-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (NMR of trimethyladamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions)

RN 46244-96-6 HCAPLUS


CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



IT 3717-61-1, 1-Adamantyltrimethylammonium iodide 53075-09-5
, N,N,N-Trimethyl-1-adamantylammonium hydroxide 128346-46-3
138764-52-0 151299-37-5
RL: PEP (Physical, engineering or chemical process); PROC (Process) (anomalous hydration behavior of)

RN 3717-61-1 HCAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 53075-09-5 HCAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide (9CI) (CA INDEX NAME)


Delacroix

10/016850




● OH^-

RN 128346-46-3 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, chloride (9CI) (CA
INDEX NAME)




● Cl^-

RN 138764-52-0 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, bromide (9CI) (CA
INDEX NAME)



● Br^-

RN 151299-37-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride (9CI) (CA
INDEX NAME)



F^-

Delacroix

L16 ANSWER 19 OF 27 USPATFULL on STN

AB There is provided a crystalline oxide material with a characteristic X-ray diffraction pattern. This material may be a layered material, which is swollen or pillared. Upon calcination of the swollen material, the layers collapse and condense upon one another in a somewhat disordered fashion to form a non-swellable material. However, the swollen layered material may be intercalated with polymeric oxide pillars to maintain layer separation, even after calcination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:82594 USPATFULL
 TITLE: Crystalline oxide material
 INVENTOR(S): Kresge, Charles T., West Chester, PA, United States
 Roth, Wieslaw J., Sewell, NJ, United States
 Simmons, Kenneth G., Williamstown, NJ, United States
 Vartuli, James C., West Chester, PA, United States
 PATENT ASSIGNEE(S): Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5250277		19931005
APPLICATION INFO.:	US 1991-811360		19911220 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Breneman, R. Bruce		
LEGAL REPRESENTATIVE:	McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1334		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
SUMM	. . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-linked with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-linking agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross linking agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .		
DETD	. . . the layers collapse and condense upon one another. These collapsed and condensed layers are not swellable and are apparently chemically linked to one another by covalent bonds.		


However, the layers of the collapsed and condensed swollen materials tend to be stacked upon one another in a. . .

IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8,
1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,
Azacyclooctane 5452-35-7, Aminocycloheptane 46244-96-6
116355-70-5
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

IT 46244-96-6
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 27 USPATFULL on STN

AB There is provided a pillared, layered crystalline oxide material and a method for making this material. This material may be prepared by intercepting a swellable layered oxide before calcination. The intercepted material is swollen and pillared. If the material is not intercepted in this manner, it is transformed into a zeolite by calcination. The pillared material may have a large degree of catalytic activity, and it may have rather porous layers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:59111 USPATFULL

TITLE: Crystalline oxide material

INVENTOR(S): Kresge, Charles T., West Chester, PA, United States
Roth, Wieslaw J., Sewell, NJ, United States
Simmons, Kenneth G., Williamstown, NJ, United States
Vartuli, James C., West Chester, NJ, United States

PATENT ASSIGNEE(S): Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5229341		19930720
APPLICATION INFO.:	US 1991-811384		19911220 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

10/016850

PRIMARY EXAMINER: Dees, Carl F.
LEGAL REPRESENTATIVE: McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.

NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,2

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1364

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


SUMM . . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-linked with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-linking agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross linking agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .

IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8,
1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,
Azacyclooctane 5452-35-7, Aminocycloheptane 46244-96-6
116355-70-5
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

IT 46244-96-6
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN



AB N,N,N-trimethyl-1-adamantylammonium hydroxide tetrahydrate, dihydrate, monohydrate, and hemihydrate are stable cryst. materials. IR comparison with tetramethylammonium hydroxide tetrahydrate of known structure suggests that the tetrahydrate is a framework clathrate species in which hydroxide ions act as hydrogen bond donors. The dihydrate appears to contain both stronger and weaker hydrogen-bonded water mols., unlike tetramethylammonium hydroxide dihydrate in which all water mols. are similar. The IR spectrum of the monohydrate is of a significantly different type, and supports the presence of HOHOH- mol. ions contg. covalent three-center OHO hydrogen bonds. A structure is proposed for the water-hydroxide ion arrangement in the monohydrate in which such HOHOH- ions are linked into a sheet through hydrogen bonds from terminal OH groups. The hemihydrate also appears to contain the HOHOH- species found in the monohydrate, and thus would also contain an equal no. of OH- ions. A structure is proposed for the hemihydrate in which alternate chains of the sheet structure of the monohydrate are dehydrated and the remaining chains are linked through OH- ions which act

Delacroix

10/016850

as both hydrogen bond donors and acceptors.

ACCESSION NUMBER: 1993:569434 HCPLUS
DOCUMENT NUMBER: 119:169434
TITLE: Hydrogen bonding. Part 47. Stoichiometry, stability, and IR spectra of N,N,N-trimethyl-1-adamantylammonium hydroxide hydrates; IR evidence for a covalent HOHOH- species in the monohydrate and hemihydrate
AUTHOR(S): Harmon, Kenneth M.; Southworth, Barbara A.; Mounts, Peggy A.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309, USA
SOURCE: Journal of Molecular Structure (1993), 296(1-2), 69-78
CODEN: JMOSEB; ISSN: 0022-2860
DOCUMENT TYPE: Journal
LANGUAGE: English
TI Hydrogen bonding. Part 47. Stoichiometry, stability, and IR spectra of N,N,N-trimethyl-1-adamantylammonium hydroxide hydrates; IR evidence for a covalent HOHOH- species in the monohydrate and hemihydrate
AB . . . IR spectrum of the monohydrate is of a significantly different type, and supports the presence of HOHOH- mol. ions contg. covalent three-center OHO hydrogen bonds. A structure is proposed for the water-hydroxide ion arrangement in the monohydrate in which such HOHOH- ions are linked into a sheet through hydrogen bonds from terminal OH groups. The hemihydrate also appears to contain the HOHOH- species found. . . the hemihydrate in which alternate chains of the sheet structure of the monohydrate are dehydrated and the remaining chains are linked through OH- ions which act as both hydrogen bond donors and acceptors.
IT 150115-20-1P 150115-21-2P 150115-22-3P
150115-23-4P
RL: PREP (Preparation)
(prepn. and IR spectroscopic properties of)
IT 150115-20-1P 150115-21-2P 150115-22-3P
150115-23-4P
RL: PREP (Preparation)
(prepn. and IR spectroscopic properties of)
RN 150115-20-1 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, tetrahydrate (9CI) (CA INDEX NAME)




RN 150115-21-2 HCPLUS

Delacroix

10/016850


CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide,
dihydrate (9CI) (CA INDEX NAME)



● OH⁻

● 2 H₂O

RN 150115-22-3 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide,
monohydrate (9CI) (CA INDEX NAME)




● OH⁻

● H₂O

RN 150115-23-4 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, hydrate
(2:1) (9CI) (CA INDEX NAME)

Delacroix



④ OH⁻

④ 1/2 H₂O

L16 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB N,N,N-Trimethyl-1-adamantylammonium fluoride forms two cryst. hydrates, a trihydrate and a hemihydrate. The IR spectrum of the trihydrate demonstrates the presence of H₂O bound by strong electrostatic hydrogen bonds in a framework clathrate structure. The trihydrate can be recrystd. from acetone to yield crystals which should be suitable for diffraction studies. The IR spectrum of bound H₂O in the hemihydrate is unlike that of H₂O in any tetraalkylammonium salt hydrate that has been previously exampd. This spectrum resembles that of the H₂F₃⁻ ion in N,N,N-trimethyl-1-adamantylammonium dihydrogen trifluoride, and a model for the hemihydrate is proposed in which a bridging H₂O mol. is bound to two F⁻ ions by unsym. covalent, three-center hydrogen bonds. An ab initio calcn. supports the proposed structure.

ACCESSION NUMBER: 1992:83090 HCAPLUS

DOCUMENT NUMBER: 116:83090

TITLE: Hydrogen bonding. Part 37. N,N,N-trimethyl-1-adamantylammonium fluoride trihydrate and hemihydrate; evidence for covalent hydrogen bonding in the hemihydrate

AUTHOR(S): Harmon, Kenneth M.; Mounts, Peggy A.; Wilson, Karen E.

CORPORATE SOURCE: Dep. Chem., Oakland Univ., Rochester, MI, 48309, USA

SOURCE: Journal of Molecular Structure (1991), 249(2-4), 161-72

CODEN: JMOB4; ISSN: 0022-2860

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Hydrogen bonding. Part 37. N,N,N-trimethyl-1-adamantylammonium fluoride trihydrate and hemihydrate; evidence for covalent hydrogen bonding in the hemihydrate

AB . . . model for the hemihydrate is proposed in which a bridging H₂O mol. is bound to two F⁻ ions by unsym. covalent, three-center hydrogen bonds. An ab initio calcn. supports the proposed structure.

IT 138863-18-0 138863-19-1

RL: PRP (Properties)

(IR and hydrogen bonding in)

IT 138863-18-0 138863-19-1


RL: PRP (Properties)

(IR and hydrogen bonding in)

RN 138863-18-0 HCAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride, trihydrate (9CI) (CA INDEX NAME)


10/016850



● F^-

● 3 H_2O


RN 138863-19-1 HCPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride, hydrate
(2:2:1) (9CI) (CA INDEX NAME)



● F^-

1/2 H_2O

L16 ANSWER 23 OF 27 HCPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
GI




AB Mol. sieves, particularly zeolites, are prep'd. using adamantane compds.

Delacroix

(I) [Z = CH₂ or covalent bond; R₁ = OH, N(X₁X₂), where independently X₁, X₂ = H, lower alkyl, or a moiety of the formula N₊(Y₁Y₂Y₃)A⁻, wherein independently Y₁, Y₂, Y₃ = lower alkyl and A⁻ = anion that is not detrimental to the formation of the mol. sieve; R₂ = H, lower alkyl; independently R₃, R₄ = H, OH, N(X₁X₂), or the moiety N₊(Y₁Y₂Y₃)A⁻ defined above] as templates. These mol. sieves are uniform in size and allow selective sepn. of hydrocarbons. Thus, 10 g 1-adamantamine was dissolved in 60 mL DMF, 29 g Bu₃N was added, and 28.4 g MeI was added dropwise while the reaction was stirred in an ice bath. The next day, crystals of N,N,N-trimethyl-1 adamantanammonium iodide (II) had formed. A 1st soln. was prep'd. by adding 5 g Na silicate (Na₂O 0.45, SiO₂ 1.46, H₂O 3.10 g), 6 mL H₂O, and 1.56 g II. A 2nd soln. was prep'd. using 0.24 g Al₂(SO₄)₃·16H₂O and 0.67 g 50 wt.% NaOH in 6 mL H₂O, and added to the 1st soln. under agitation to obtain a milky soln. The reactor was closed and heated at 140.degree. for 6 days. The resulting solids were washed 5 times with deionized H₂O, followed by once each with MeOH and Me₂CO, and were shown to correspond to zeolite SSZ-13.


ACCESSION NUMBER: 1987:499231 HCPLUS
 DOCUMENT NUMBER: 107:99231
 TITLE: Process for preparing molecular sieves using adamantan template
 INVENTOR(S): Zones, Stacey I.
 PATENT ASSIGNEE(S): Chevron Research Co., USA
 SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4665110	A	19870512	US 1986-823700	19860129
PRIORITY APPLN. INFO.:			US 1986-823700	19860129
AB Mol. sieves, particularly zeolites, are prep'd. using adamantan compds. (I) [Z = CH ₂ or covalent bond; R ₁ = OH, N(X ₁ X ₂), where independently X ₁ , X ₂ = H, lower alkyl, or a moiety of the formula N ₊ (Y ₁ Y ₂ Y ₃)A ⁻ , . . .]				
IT	700-57-2 768-94-5 768-95-6 3717-61-1, N,N,N-Trimethyl-1-adamantanammonium iodide 39234-35-0 40505-99-5, N,N,N-Trimethyl-2-adamantanammonium iodide 53075-09-5 53075-10-8 109954-44-1			
RL: USES (Uses) (template, in SSZ-type zeolite manuf.)				
IT	3717-61-1, N,N,N-Trimethyl-1-adamantanammonium iodide 53075-09-5			
RL: USES (Uses) (template, in SSZ-type zeolite manuf.)				
RN	3717-61-1 HCPLUS			
CN	Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)			



O I-

RN 53075-09-5 HCPLUS
 CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide (9CI)
 (CA INDEX NAME)



② OH-

L16 ANSWER 24 OF 27 USPATFULL on STN

AB Conjugated ketone compounds of the formula: ##STR1## wherein Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or more substituents selected from the group consisting of chlorine, bromine, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, trifluoromethyl and methylenedioxy, R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.7 -C.sub.8 aralkyl or adamantyl, R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl or C.sub.3 -C.sub.6 cycloalkyl, or when R.sub.1 and R.sub.2 are taken together with the nitrogen atom to which they are attached, they form a heterocyclic amino group containing up to 8 carbon atoms, A is straight or branched C.sub.1 -C.sub.3 alkylene, N-[4-(p-chlorophenyl)-4-oxo-2-trans-butenyl]morpholine and N-[4-(p-methoxyphenyl)-4-oxo-2-trans-butenyl]piperidine being excluded, and their non-toxic salts, which are useful as blood platelet anti-aggregative agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 83:56156 USPATFULL

TITLE: Conjugated ketone compounds in preventing platelet thrombosis

INVENTOR(S):
 Kojima, Atsuyuki, Hyogo, Japan
 Irie, Tsunemasa, Hyogo, Japan
 Harada, Shuichi, Osaka, Japan
 Kameno, Yoshito, Osaka, Japan
 Katsube, Junki, Osaka, Japan
 Yamamoto, Hisao, Hyogo, Japan

PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4418079		19831129
APPLICATION INFO.:	US 1981-335522		19811229 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1980-217043, filed on 16 Dec 1980, now abandoned which is a continuation of Ser. No. US 1978-973639, filed on 27 Dec 1978, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-2938	19780113
	JP 1978-2939	19780113
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Friedman, Stanley J.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	551	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Conjugated ketone compounds in preventing platelet thrombosis
 AB Conjugated ketone compounds of the formula: ##STR1## wherein
 Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or more
 substituents. . .
 SUMM The present invention relates to conjugated ketone compounds,
 and their production and use.
 SUMM The objective conjugated ketone compounds are representable by
 the formula: ##STR2## wherein Ar is naphthyl, furyl, thienyl, or phenyl
 optionally bearing one or. . .
 SUMM The conjugated ketone compounds [I] can form acid addition
 salts (e.g. hydrochlorides, hydrobromides, sulfates, oxalates, citrates,
 fumarates, maleates, tartrates, etc.), and these. . .
 SUMM The conjugated ketone compounds [I] and their non-toxic salts
 inhibit aggregation of blood platelets and are useful for prevention of
 intravascular thrombosis,. . .
 SUMM Among the conjugated ketone compounds [I], those of the
 following formula are preferred: ##STR3## wherein Ar' is naphthyl,
 furyl, thienyl or phenyl optionally. . .
 SUMM The conjugated ketone compounds [I] and their non-toxic salts
 can be administered to warm-blooded animals either alone or in
 combination with pharmaceutically. . .
 SUMM The conjugated ketone compounds [I] can be prepared as shown
 in the following scheme: ##STR6## wherein Ar, R.sub.1, R.sub.2 and A
 are. . .
 SUMM Pharmacological evaluation has indicated the conjugated ketone
 compounds [I] of the invention show an anti-aggregative activity for
 blood platelets.
 SUMM The conjugated ketone compounds [I] were also tested ex vivo
 in rats where ADP or collagen was used to induce aggregation in. . .
 SUMM The conjugated ketone compounds [I] are superior blood
 platelet anti-aggregative agents to the conjugated ketone
 derivatives as disclosed in U.S. Pat. No. 4,012,515 in many respects.
 The compounds as disclosed in that patent are. . .
 IT 71678-41-6P 71678-42-7P 71678-43-8P 71678-44-9P 71678-45-0P
 71678-46-1P 71678-47-2P 71678-48-3P 71678-49-4P 71678-50-7P
 71678-51-8P 71678-52-9P 71678-53-0P 71678-54-1P 71678-55-2P
 71678-57-4P 71678-58-5P 71678-59-6P 71678-60-9P 71678-61-0P
 71678-62-1P 71678-63-2P 71678-64-3P 71678-65-4P 71678-66-5P

71678-67-6P 71678-68-7P 71678-69-8P 71679-44-2P 71679-45-3P
 71679-46-4P 71679-47-5P 71679-48-6P 71679-49-7P 71679-50-0P
 71679-51-1P 71679-52-2P 71679-53-3P 71679-54-4P
 71679-55-5P 71679-56-6P 71679-57-7P 71679-58-8P 71679-59-9P
 71679-60-2P 71679-61-3P 71895-92-6P 71895-93-7P 71895-97-1P
 (prepn. and blood platelet aggregation inhibitory activity of)


IT 71679-52-2P

(prepn. and blood platelet aggregation inhibitory activity of)

RN 71679-52-2 USPATFULL

CN 2-Buten-1-one, 4-(methyltricyclo[3.3.1.13, 7]dec-1-ylamino)-1-phenyl-,
 hydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



• HCl

L16 ANSWER 25 OF 27 USPATFULL on STN

AB Compounds of the formula ##STR1## wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula ##STR2## R.sup.1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl;

R.sup.2 is --H or lower aliphatic hydrocarbyl;

R.sup.3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R.sup.4, alkylene;

R.sup.4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R.sup.3, alkylene;

or R.sup.2, R.sup.3 and R.sup.4, together with the carbon to which each is bound, are adamantyl; and

n is 3, 4 or 5;

and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are

10/016850

discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 81:985 USPATFULL
TITLE: Acylhydrocarbylaminooalkanoic acids, compositions and uses
INVENTOR(S): Krastinat, Walter, Constance, Germany, Federal Republic of
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4243678		19810106
APPLICATION INFO.:	US 1978-969701		19781215 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	LU 1977-78865	19771230
	CH 1978-6504	19780614
	CH 1978-6505	19780614

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Berman, Aisenberg & Platt
NUMBER OF CLAIMS: 100
EXEMPLARY CLAIM: 1,51
LINE COUNT: 3768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


SUMM . . . unsaturation is either mono (as in allyl) or multiple (as in butadienyl), and multiple unsaturation can (but need not) be conjugated; includes straight-chain or branched alkyl radicals with, e.g., from 1 to 7 carbon atoms; straight-chain alkyl is, e.g., methyl, ethyl, . . .

IT	4521-61-3P	4789-08-6P	60737-65-7P	71454-82-5P	71454-87-0P
	71454-88-1P	71454-91-6P	71454-93-8P	71454-95-0P	71454-96-1P
	71454-98-3P	71454-99-4P	71455-00-0P	71455-01-1P	71455-02-2P
	71455-03-3P	71455-04-4P	71455-06-6P	71455-07-7P	
	71455-11-3P	71455-13-5P	71455-14-6P	71455-15-7P	71455-17-9P
	71455-30-6P	71455-31-7P	71455-32-8P	71455-33-9P	71455-34-0P
	71455-36-2P	71455-37-3P	71455-38-4P	71455-39-5P	71455-40-8P
	71455-41-9P	71455-42-0P	71455-43-1P	71455-44-2P	
	71455-45-3P	71455-46-4P	71455-47-5P	71455-48-6P	71455-50-0P
	71455-51-1P	71455-52-2P	71455-53-3P	71455-54-4P	71455-55-5P
	71455-56-6P	71455-57-7P	71455-58-8P	71455-59-9P	71455-60-2P
	71455-61-3P	71455-62-4P	71455-63-5P	71455-64-6P	71510-64-0P
	71510-65-1P	71510-66-2P	71510-67-3P	71510-68-4P	71510-69-5P
	71510-70-8P	71563-92-3P	71564-71-1P	74296-84-7P	74296-85-8P
	74296-86-9P	74296-88-1P	74296-90-5P	74296-91-6P	74296-93-8P
	74296-95-0P	74296-96-1P	74296-97-2P	74296-98-3P	74296-99-4P
	74297-01-1P	74297-02-2P	74297-03-3P	74297-04-4P	74297-05-5P
	74297-06-6P	74297-07-7P	74297-09-9P	74297-10-2P	74297-12-4P
	74297-13-5P	74297-14-6P	74297-15-7P	74297-16-8P	74297-17-9P
	74297-18-0P	74297-19-1P	74297-20-4P	74297-21-5P	74297-23-7P
	74297-24-8P	74297-25-9P	74297-26-0P	74297-27-1P	74297-28-2P
	74297-29-3P	74297-30-6P	74297-31-7P	74297-32-8P	74297-33-9P
	74297-34-0P	74297-38-4P	74297-39-5P	74297-41-9P	74297-45-3P
	74304-86-2P	78331-41-6P	78331-42-7P	78331-43-8P	78331-44-9P


Delacroix

10/016850

78331-45-0P 78331-46-1P 78331-47-2P
(prepn. of)
IT 71455-04-4P 71455-43-1P
(prepn. of)
RN 71455-04-4 USPATFULL
CN Butanoic acid, 4-[(4-chlorobenzoyl)tricyclo[3.3.1.13,7]dec-1-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 71455-43-1 USPATFULL
CN Butanoic acid, 4-[(4-chlorobenzoyl)tricyclo[3.3.1.13,7]dec-1-ylamino]- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB Fifty title compds. trans-RCOCH:CHZNR1R2 (I; R = naphthyl, furyl, thiienyl, Ph optionally substituted by .gtoreq.1 of Cl, Br, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, CF3, methylenedioxy; Z = C1-3 alkylene; R1 = C1-6 alkyl, C3-5 alkenyl, C3-6 cycloalkyl, C7-8 aralkyl, adamantyl; R2 = C1-6 alkyl, C3-5 alkenyl, C3-6 cycloalkyl; NR1R2 = heterocyclic amino contg. .gtoreq.8 C atoms) and their acid addn. salts were prep'd. Thus, I.HBr (R = Ph, Z = CH2, R1 = R2 = Et) was prep'd. from Et2NH by sequential treatment with HC.tplbond.CCH2Br, EtMgBr, PhCHO, LiAlH4, MnO2, and HBr. The blood platelet antiaggregative activities of I were assessed in rats and in vitro. Compared with the known butyrophenone neuroleptics, I show increased antiaggregative activity with smaller or no neuroleptic properties.

ACCESSION NUMBER: 1980:426110 HCAPLUS
DOCUMENT NUMBER: 93:26110
TITLE: Conjugated ketones useful as blood platelet antiaggregative agents
INVENTOR(S): Kojima, Atsuyuki; Irie, Tsunemasa; Harada, Shuichi; Kameno, Yoshito; Katsume, Junki; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Brit. UK Pat. Appl., 13 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

Delacroix

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2012749	A1	19790801	GB 1979-1123	19790111
GB 2012749	B2	19821222		
JP 54098755	A2	19790803	JP 1978-2938	19780113
JP 54098733	A2	19790803	JP 1978-2939	19780113
JP 61025020	B4	19860613		
CA 1151164	A1	19830802	CA 1979-319260	19790108
DK 7900127	A	19790714	DK 1979-12779	19790111
FR 2414495	A1	19790810	FR 1979-667	19790111
BE 873429	A1	19790712	BE 1979-192855	19790112
SE 7900290	A	19790714	SE 1979-290	19790112
AU 7943337	A1	19790719	AU 1979-43337	19790112
AU 523214	B2	19820715		
ES 476818	A1	19791201	ES 1979-476818	19790112
AT 7900232	A	19810115	AT 1979-232	19790112
AT 363461	B	19810810		
HU 19750	O	19810428	HU 1979-SU1004	19790112
HU 177514	P	19811028		
CH 640213	A	19831230	CH 1979-313	19790112
NL 7900307	A	19790717	NL 1979-307	19790115
US 4418079	A	19831129	US 1981-335522	19811229
PRIORITY APPLN. INFO.:			JP 1978-2938	19780113
			JP 1978-2939	19780113
			US 1978-973639	19781227
			US 1980-217043	19801216

TI **Conjugated ketones useful as blood platelet antiaggregative agents**


IT 71678-41-6P 71678-42-7P 71678-43-8P 71678-44-9P 71678-45-0P
 71678-46-1P 71678-47-2P 71678-48-3P 71678-49-4P 71678-50-7P
 71678-51-8P 71678-52-9P 71678-53-0P 71678-54-1P 71678-55-2P
 71678-57-4P 71678-58-5P 71678-59-6P 71678-60-9P 71678-61-0P
 71678-62-1P 71678-63-2P 71678-64-3P 71678-65-4P 71678-66-5P
 71678-67-6P 71678-68-7P 71678-69-8P 71679-44-2P 71679-45-3P
 71679-46-4P 71679-47-5P 71679-48-6P 71679-49-7P 71679-50-0P
 71679-51-1P **71679-52-2P** 71679-53-3P 71679-54-4P
 71679-55-5P 71679-56-6P 71679-57-7P 71679-58-8P 71679-59-9P
 71679-60-2P 71679-61-3P 71895-92-6P 71895-93-7P 71895-97-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and blood platelet aggregation inhibitory activity of)

IT **71679-52-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and blood platelet aggregation inhibitory activity of)

RN 71679-52-2 HCPLUS

CN 2-Buten-1-one, 4-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-1-phenyl-,
 hydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



O HCl

L16 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB Aliphatic primary amines react with 1-bromoadamantane (I) only at 170-80. degree. (sealed tube reaction). Aliphatic secondary amines require 200-10. degree. to react with I. Also prep'd. was 1,1' -diadamantylamine. The aromatic amines react with I in 2 ways. Thus PhNH₂ gave .apprx.20% N-(adamant-1-yl)aniline (II) and .apprx.7% 4-(adamant-1-yl)aniline. Similarly, o-MeC₆H₄NH₂ reacted with I to give 26.2% 2-methyl-4-(adamant-1-yl)aniline and 4.1% 2-methyl-N-(adamant-1-yl)aniline. However, m-MeC₆H₄NH₂ or p-MeC₆H₄-NH₂ gave only 3-methyl-N-(adamant-1-yl)aniline (III) or 4-methyl-N-(adamant-1-yl)aniline, resp. PhNMe₂ also gave only 1 product: 4-(adamant-1-yl)dimethylaniline. The methylation of II or III gave, resp., N-methyl-N-(adamant-1-yl)-aniline and 3-methyl-N-methyl-N-(adamant-1-yl)aniline. The tertiary amines, due to the steric hindrance, are not **conjugated** through the central N atom.

ACCESSION NUMBER: 1969:412643 HCAPLUS

DOCUMENT NUMBER: 71:12643

TITLE: Adamantane and its derivatives. XVIII. Reaction of 1-bromoadamantane with amines

AUTHOR(S): Stepanov, F. N.; Stolyarov, Z. E.

CORPORATE SOURCE: Kiev. Politekh. Inst., Kiev, USSR

SOURCE: Zhurnal Organicheskoi Khimii (1969), 5(3), 537-41

CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB . . . methylation of II or III gave, resp., N-methyl-N-(adamant-1-yl)-aniline and 3-methyl-N-methyl-N-(adamant-1-yl)aniline. The tertiary amines, due to the steric hindrance, are not **conjugated** through the central N atom.

IT 99-97-8P 121-69-7P 281-23-2P 609-72-3P 3717-50-8P 3717-60-0P

3788-37-2P 7123-77-5P 19984-34-0P 19984-37-3P 19984-39-5P

19984-51-1P 22947-32-6P 22947-33-7P 22947-34-8P 22947-36-0P

22947-39-3P 22947-40-6P 22947-41-7P 22947-42-8P 22947-46-2P

22947-47-3P 22947-50-8P 22947-51-9P 22947-52-0P 22947-53-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


IT 3788-37-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 3788-37-2 HCAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-diethyl- (9CI) (CA INDEX NAME)

10/016850



=> file stnguide

Delacroix